睿知中国医院研究地图
候选清单

哈尔滨哈尔滨医科大学

哈尔滨医科大学附属肿瘤医院

Harbin Medical University Cancer Hospital

在本站收录的 61 种疾病中,这家医院列在其中 14 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

哈尔滨医科大学附属肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma0 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma12 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma58 篇牵头论文
  4. 胃癌Stomach cancer66 篇牵头论文
  5. 肺癌Lung cancer156 篇牵头论文
  6. 胰腺癌Pancreatic cancer27 篇牵头论文
  7. 乳腺癌Breast cancer168 篇牵头论文牵头 1 项开放试验
  8. 胶质瘤Glioma14 篇牵头论文
  9. 骨肉瘤Osteosarcoma2 篇牵头论文
  10. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  11. 多发性骨髓瘤Multiple myeloma6 篇牵头论文
  12. 淋巴瘤Lymphoma26 篇牵头论文
  13. 范可尼贫血Fanconi anaemia0 篇牵头论文
  14. IgA 肾病IgA nephropathy0 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、脊索瘤、神经母细胞瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、冠心病、先天性心脏病、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年没有牵头鼻咽癌的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

哈尔滨有 1 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.4%。

牵头论文
12
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 1120222023: 1120232024: 4420242025: 112025

哈尔滨有 1 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-08
    发布
    登记号
    NCT07700667

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 21 家列出的医院为研究中心十堰、南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、重庆、长春

  2. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    发布
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

  3. 即将招募
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    分期
    II期
    开始
    2026-06
    发布
    登记号
    NCT07623642

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、哈尔滨

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫治疗新辅助与综合治疗分子标志物与基因
论文中的科室肿瘤内科放疗科影像/核医学科病理/检验科
牵头的论文12
  1. Intratumoral and peritumoral heterogeneity based on CT to predict the pathological response after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.2026International journal of surgery (London, England)免费全文
  2. Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.2025BMC medicine免费全文
  3. Analysis of multiple programmed cell death-related prognostic genes and functional validations of necroptosis-associated genes in oesophageal squamous cell carcinoma.2024EBioMedicine免费全文
  4. Nucleoporin 93, a new substrate of the E3 ubiquitin protein ligase HECTD1, promotes esophageal squamous cell carcinoma progression.2024Human cell
  5. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).2024International journal of surgery (London, England)免费全文
  6. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.2024Journal of translational medicine免费全文
  7. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.2023Cancer immunology, immunotherapy : CII免费全文
  8. Identification and validation of an eight-lncRNA signature that predicts prognosis in patients with esophageal squamous cell carcinoma.2022Cellular & molecular biology letters免费全文
  9. Photodynamic therapy induces human esophageal carcinoma cell pyroptosis by targeting the PKM2/caspase-8/caspase-3/GSDME axis.2021Cancer letters
  10. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling.2021Cell cycle (Georgetown, Tex.)免费全文
  11. Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma.2021Chemico-biological interactions
  12. UBE2T Contributes to the Prognosis of Esophageal Squamous Cell Carcinoma.2021Pathology oncology research : POR免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)19
  1. Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma进行中,不再招募NCT07682376牵头方(推断)II期2026-06 启动
  2. A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.即将招募NCT07623642研究中心II期2026-06 启动
  3. SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07700667研究中心II期2026-08 启动
  4. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  5. A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma状态不明NCT06512428研究中心II期2024-03 启动
  6. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  7. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  8. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  9. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  10. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).已终止NCT04949256研究中心III期2021-07 启动
  11. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  12. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  13. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  14. Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma状态不明NCT03817567研究中心I/II期2018-07 启动
  15. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
  16. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma已完成NCT03469557研究中心II期2017-07 启动
  17. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  18. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  19. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02611700研究中心III期2015-11 启动
PubMed 以外找到的论文(未计入)32
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncology论文
  2. 272. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS CONVERSION THERAPY FOR LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM STUDY2025Diseases of the Esophagus论文
  3. 287. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESPRIT): A PHASE II, SINGLE-ARM STUDY2025Diseases of the Esophagus论文
  4. 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical2025Annals of Oncology论文
  5. 349. PATHOLOGIC COMPLETE RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CANCER: DO DIVERSE NEOADJUVANT MODALITIES PREDICT PROGNOSTIC DIFFERENCES?2025Diseases of the Esophagus论文
  6. Camrelizumab combined with paclitaxel and nedaplatin as conversion therapy for locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm exploratory study.2025Journal of Clinical Oncology论文
  7. Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research.2025Journal of Clinical Oncology论文
  8. LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 study2025Annals of Oncology会议摘要
  9. Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study.2025Journal of Clinical Oncology会议摘要
  10. Tumor Microenvironment-Guided Fine-Tuning of Pathology Foundation Models for Esophageal Squamous Cell Carcinoma Immunotherapy Response Prediction2025Lecture notes in computer science会议论文
  11. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncology论文
  12. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  13. 189P Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncology论文
  14. Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis2023Cancer Research会议摘要
  15. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  16. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  17. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  18. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  19. Development and validation of a survival prediction model for patients with esophageal squamous cell carcinoma of the thoracic segment with pT1-2 lymph node metastasis2023Research Square预印本
  20. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncology会议摘要
  21. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncology论文
  22. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncology论文
  23. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncology论文
  24. 65P Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research2021Annals of Oncology论文
  25. 66P Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research2021Annals of Oncology论文
  26. CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  27. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  28. Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  29. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要
  30. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  31. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  32. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 58 篇,占 0.4%。

牵头论文
58
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
13
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 121220222023: 151520232024: 101020242025: 11112025

哈尔滨有 4 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 13

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    First in Human Study of SIM0610 in Solid Tumors
    分期
    I期
    开始
    2026-01
    发布
    登记号
    NCT07348211

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、哈尔滨、沈阳、重庆

  2. 正在招募
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    分期
    I/II期
    开始
    2026-05
    发布
    登记号
    NCT07547553

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、沈阳、福州、蚌埠、郑州、长春

  3. 正在招募
    Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
    分期
    II/III期
    开始
    2025-02
    发布
    登记号
    NCT06796803

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属中山医院;另有 1 家列出的医院为研究中心上海、哈尔滨

  4. 正在招募
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-05
    发布
    登记号
    NCT06954467

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、合肥、哈尔滨、沈阳、郑州、长沙

  5. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    发布
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  6. 正在招募
    NWRD06 DNA Plasmid for HCC After Curative Resection.
    分期
    II期
    开始
    2025-12
    发布
    登记号
    NCT07324304

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、哈尔滨、杭州

  7. 正在招募
    Phase 2 Study of WGI-0301 for Advanced HCC
    分期
    II期
    开始
    2024-07
    发布
    登记号
    NCT06309485

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心南昌、哈尔滨、成都、杭州、武汉、长沙

  8. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    发布
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

  9. 正在招募
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    分期
    I/II期
    开始
    2021-11
    发布
    登记号
    NCT05024214

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、哈尔滨、大连、天津、广州、杭州、沈阳、珠海、福州、蚌埠、郑州、长春

  10. 即将招募
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    分期
    未注明
    开始
    2026-07
    发布
    登记号
    NCT07724951

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属中山医院;另有 6 家列出的医院为研究中心上海、南宁、哈尔滨、广州、青岛

  11. 即将招募
    Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
    分期
    I/II期
    开始
    2026-09
    发布
    登记号
    NCT07761286

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心哈尔滨

  12. 即将招募
    JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
    分期
    III期
    开始
    2026-10
    发布
    登记号
    NCT07823348

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、哈尔滨

  13. 即将招募
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    分期
    不分期
    开始
    2025-06
    发布
    登记号
    NCT07010588

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学人民医院;另有 8 家列出的医院为研究中心北京、哈尔滨、武汉、济南、西安、重庆、长春、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像、人工智能与早期发现复发与预后免疫与靶向药物
论文中的科室影像/核医学科肿瘤内科普外/肝胆胰外科放疗科
牵头的论文58
  1. In Situ Assembly of Transformable Monopeptide on Activated Neutrophils Attenuates NETs-Induced Hepatocellular Carcinoma Metastasis by Disrupting NE Nuclear Translocation.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Integrating lesser omentum adipose CT in dual-phase tumor imaging: A multi-label deep learning framework for preoperative microvascular invasion prediction and survival analysis in hepatocellular carcinoma.2026Computer methods and programs in biomedicine
  3. An etiology-stratified single-cell atlas identifies FABP4 as a prognostic marker for MASLD-related HCC.2026Journal of hepatology
  4. Deep Learning-Based Prediction of Microvascular Invasion and Survival Outcomes in Hepatocellular Carcinoma Using Dual-phase CT Imaging of Tumors and Lesser Omental Adipose: A Multicenter Study.2025Academic radiology
  5. Targeted nanosensitizer-augmented sono-immunotherapy with STING agonist to remodel the immune microenvironment in hepatocellular carcinoma.2025Acta biomaterialia
  6. Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors.2025BMC gastroenterology免费全文
  7. Targeting RECQL4 in hepatocellular carcinoma: from prognosis to therapeutic potential.2025BMC medical genomics免费全文
  8. TAPP@NBs combined with GSNO to enhance the anti-liver cancer effect of sonodynamic therapy.2025Biomedical materials (Bristol, England)
  9. Comparing neoadjuvant targeted therapy plus transarterial chemoembolization versus triple therapy including immunotherapy in hepatocellular carcinoma: a Chinese multicentre study.2025Cancer immunology, immunotherapy : CII免费全文
  10. Comparative analysis of metabolome and transcriptomes to explore the inhibited influence of sonodynamic therapy combined with lonidamine on hepatocellular carcinoma.2025Drug delivery免费全文
  11. The transcription factor HOXB7 significantly enhances the expression of PIGT through the Wnt/β-catenin signaling pathway, thereby promoting the proliferation and deterioration of HCC.2025Expert review of anticancer therapy
  12. TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study.2025Frontiers in immunology免费全文
  13. Macrophage hitchhiking for systematic suppression in postablative multifocal HCC.2025Hepatology (Baltimore, Md.)
  14. Ultrasound-responsive nanobubble-mediated sonodynamic therapy sensitizes disulfidptosis in the treatment of liver hepatocellular carcinoma.2025Ultrasonics sonochemistry免费全文
  15. NIR-II Light-Actuated Nanomotors for Enhanced Photoimmunotherapy Toward Hepatocellular Carcinoma.2024ACS applied materials & interfaces
  16. Reply to the Letter from Qian Ren and Yanjun Wang About the Article, "LI-RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection".2024Annals of surgical oncology
  17. Three-dimensional morphology scoring of hepatocellular carcinoma stratifies prognosis and immune infiltration.2024Computers in biology and medicine
  18. SHR6390 Combined with Cabozantinib Inhibits Tumor Progression in the Hepatocellular Carcinoma Mouse Model.2024Current gene therapy
  19. CsxWO3@NBs as a Multi-Image Guided Photothermal/Photodynamic Combination Therapy Platform for the Treatment of Hepatocellular Carcinoma.2024International journal of nanomedicine免费全文
  20. Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy.2024Journal for immunotherapy of cancer免费全文
  21. The mechanism and experimental verification of Ixeris sonchifolia promoting apoptosis of hepatocellular carcinoma based on network pharmacology: Ixeris sonchifolia Induces Hepatocellular Carcinoma Apoptosis via the PI3K/AKT Pathway.2024Journal of ethnopharmacology
  22. Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms.2024Journal of nanobiotechnology免费全文
  23. Clinical prediction of microvascular invasion in hepatocellular carcinoma using an MRI-based graph convolutional network model integrated with nomogram.2024The British journal of radiology免费全文
  24. Prognostic factors in patients with first diagnosis of hepatocellular carcinoma presenting with pulmonary metastasis and construction of a clinical prediction model.2024Updates in surgery
  25. LI-RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection.2023Annals of surgical oncology
  26. Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma.2023BMC bioinformatics免费全文
  27. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.2023BMC cancer免费全文
  28. BTF3 promotes proliferation and glycolysis in hepatocellular carcinoma by regulating GLUT1.2023Cancer biology & therapy免费全文
  29. A radiomics signature associated with underlying gene expression pattern for the prediction of prognosis and treatment response in hepatocellular carcinoma.2023European journal of radiology
  30. Interleukin-35 expression promotes hepatocellular carcinogenesis by inducing γδ T-cell exhaustion.2023Genomics
  31. The combination of circulating IgM and geriatric nutritional risk index predicts the prognostic of hepatocellular carcinoma patients who underwent immune checkpoint inhibitors.2023International immunopharmacology
  32. Recent advances in natural polysaccharides against hepatocellular carcinoma: A review.2023International journal of biological macromolecules
  33. Sonosensitizer Nanoplatforms Augmented Sonodynamic Therapy-Sensitizing Shikonin-Induced Necroptosis Against Hepatocellular Carcinoma.2023International journal of nanomedicine免费全文
  34. IR-820@NBs Combined with MG-132 Enhances the Anti-Hepatocellular Carcinoma Effect of Sonodynamic Therapy.2023International journal of nanomedicine免费全文
  35. Sono-Immunotherapy Mediated Controllable Composite Nano Fluorescent Probes Reprogram the Immune Microenvironment of Hepatocellular Carcinoma.2023International journal of nanomedicine免费全文
  36. Establishment and Validation of the LI-RADS Morphologic Type II Hepatocellular Carcinoma Early Recurrence Risk Scoring System.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  37. ZMIZ1 Upregulation of TET3-Mediated Hydroxymethylation Induces M2 Polarization of Kupffer Cells in Hepatocellular Carcinogenesis by Mediating Notch1/c-Myc Signaling.2023Laboratory investigation; a journal of technical methods and pathology
  38. Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis.2023Pathology, research and practice
  39. Clinical value of combined preoperative-postoperative neutrophil-to-lymphocyte ratio in predicting hepatocellular carcinoma prognosis after radiofrequency ablation.2023The British journal of radiology免费全文
  40. Pharmacokinetic analysis of different contrast agents on multiphase enhanced MRI for microvascular invasion: preoperative prediction in hepatocellular carcinoma.2022Acta radiologica (Stockholm, Sweden : 1987)
  41. Preoperative PDW levels predict pulmonary metastasis in patients with hepatocellular carcinoma.2022BMC cancer免费全文
  42. Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.2022BMC gastroenterology免费全文
  43. Lean body mass predicts postoperative liver failure in patients with hepatocellular carcinoma.2022Cancer biomarkers : section A of Disease markers免费全文
  44. Dose of intra-operative opioids has no impact on recurrence or survival in primary liver cancer.2022Cancer medicine免费全文
  45. A Ferroptosis-Related LncRNA Signature Associated with Prognosis, Tumor Immune Environment, and Genome Instability in Hepatocellular Carcinoma.2022Computational and mathematical methods in medicineRCT免费全文
  46. Development and validation of four ferroptosis-related gene signatures and their correlations with immune implication in hepatocellular carcinoma.2022Frontiers in immunology免费全文
  47. A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma.2022Future oncology (London, England)
  48. RNA-Seq Explores the Mechanism of Oxygen-Boosted Sonodynamic Therapy Based on All-in-One Nanobubbles to Enhance Ferroptosis for the Treatment of HCC.2022International journal of nanomedicine免费全文
  49. Comparison of 8spheres polyvinyl alcohol microsphere and gelatin sponge particle efficacy for transcatheter arterial chemoembolization in stages A to B patients with hepatocellular carcinoma.2022Journal of cancer research and therapeutics
  50. Dynamic Contrast-Enhanced Ultrasonography with Sonazoid for Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma.2022Ultrasound in medicine & biology
  51. Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation Based on Logistic Regression Analysis.2022Ultrasound in medicine & biology
  52. Value of gadoxetic acid-enhanced MRI for microvascular invasion of small hepatocellular carcinoma: a retrospective study.2021BMC medical imaging免费全文
  53. Circ_0004018 suppresses cell proliferation and migration in hepatocellular carcinoma via miR-1197/PTEN/PI3K/AKT signaling pathway.2021Cell cycle (Georgetown, Tex.)免费全文
  54. Enhanced expression of miR-889 forecasts an unfavorable prognosis and facilitates cell progression in hepatocellular carcinoma.2021Diagnostic pathology免费全文
  55. Synergistic Anticancer Strategy of Sonodynamic Therapy Combined with PI-103 Against Hepatocellular Carcinoma.2021Drug design, development and therapy免费全文
  56. Novel small molecule inhibitors of the transcription factor ETS-1 and their antitumor activity against hepatocellular carcinoma.2021European journal of pharmacology
  57. Oxygen-sufficient lipid nanobubbles combined with UTMD for enhanced sonodynamic therapy of Hep-G2 cells.2021Journal of biomedical materials research. Part B, Applied biomaterials
  58. Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma.2021Journal of nanobiotechnology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)36
  1. Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma即将招募NCT07761286研究中心I/II期2026-09 启动
  2. First in Human Study of SIM0610 in Solid Tumors正在招募NCT07348211研究中心I期2026-01 启动
  3. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC正在招募NCT07547553研究中心I/II期2026-05 启动
  4. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study即将招募NCT07724951研究中心2026-07 启动
  5. JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer即将招募NCT07823348研究中心III期2026-10 启动
  6. NWRD06 DNA Plasmid for HCC After Curative Resection.正在招募NCT07324304研究中心II期2025-12 启动
  7. Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)正在招募NCT06796803研究中心II/III期2025-02 启动
  8. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma正在招募NCT06954467研究中心II期2025-05 启动
  9. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk即将招募NCT07010588研究中心不分期2025-06 启动
  10. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  11. Phase 2 Study of WGI-0301 for Advanced HCC正在招募NCT06309485研究中心II期2024-07 启动
  12. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  13. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors正在招募NCT05024214研究中心I/II期2021-11 启动
  14. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)已终止NCT06487559研究中心I期2024-09 启动
  15. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  16. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  17. Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)状态不明NCT04741165研究中心II期2021-01 启动
  18. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  19. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  20. The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma已完成NCT04542837研究中心II期2020-09 启动
  21. Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma已完成NCT04401800研究中心II期2020-09 启动
  22. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  23. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  24. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  25. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  26. A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma已完成NCT04194801研究中心I/II期2019-12 启动
  27. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  28. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)已完成NCT03713593研究中心III期2018-12 启动
  29. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  30. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma已完成NCT03434379研究中心III期2018-03 启动
  31. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  32. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  33. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC已完成NCT03516071研究中心II期2017-05 启动
  34. Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT02953743研究中心I期2016-09 启动
  35. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma已完成NCT02508467研究中心I期2015-07 启动
  36. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma已完成NCT01988493研究中心I/II期2014-01 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 66 篇,占 0.7%。

牵头论文
66
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
16
由其他机构牵头
每年牵头的论文数
2021: 151520212022: 6620222023: 7720232024: 171720242025: 20202025

哈尔滨有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 16

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2025-02
    发布
    登记号
    NCT06731478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川

  2. 正在招募
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    分期
    III期
    开始
    2025-05
    发布
    登记号
    NCT06901531

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、成都、杭州、武汉、石家庄、福州、西宁、郑州

  3. 正在招募
    A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
    分期
    III期
    开始
    2025-08
    发布
    登记号
    NCT07023315

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、哈尔滨、石家庄、福州

  4. 正在招募
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    分期
    I期
    开始
    2025-07
    发布
    登记号
    NCT07066657

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、杭州、武汉、郑州、重庆、长沙

  5. 正在招募
    Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
    分期
    II期
    开始
    2025-09
    发布
    登记号
    NCT07102901

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心哈尔滨、郑州

  6. 正在招募
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    分期
    II期
    开始
    2025-12
    发布
    登记号
    NCT07127822

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院;另有 8 家列出的医院为研究中心北京、哈尔滨、天津、太原、成都、石家庄、西安、郑州、青岛

  7. 正在招募
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    分期
    II/III期
    开始
    2024-02
    发布
    登记号
    NCT06221748

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、厦门、哈尔滨、徐州、成都、昆明、武汉、济南、郑州、长沙、青岛

  8. 正在招募
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    分期
    I/II期
    开始
    2024-06
    发布
    登记号
    NCT06324357

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、南京、哈尔滨、天津、杭州、郑州、长春

  9. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    发布
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  10. 正在招募
    To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
    分期
    II/III期
    开始
    2024-08
    发布
    登记号
    NCT06504732

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心哈尔滨、沈阳

  11. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    发布
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、洛阳、石家庄、福州、蚌埠、西宁、郑州、重庆、银川、长春、长沙、青岛

  12. 正在招募
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06632262

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州

  13. 正在招募
    A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
    分期
    I期
    开始
    2024-12
    发布
    登记号
    NCT06783569

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心哈尔滨、沈阳

  14. 正在招募
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    分期
    III期
    开始
    2023-04
    发布
    登记号
    NCT05918094

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 7 家列出的医院为研究中心上海、南昌、哈尔滨、大连、广州、成都、武汉、郑州

  15. 正在招募
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    II期
    开始
    2023-11
    发布
    登记号
    NCT06155383

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、厦门、哈尔滨、广州、成都、昆明、济南、福州、郑州

  16. 正在招募
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    分期
    I期
    开始
    2021-06
    发布
    登记号
    NCT04900818

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能手术腹膜转移与晚期
论文中的科室消化/肝病科肿瘤内科影像/核医学科病理/检验科
牵头的论文66
  1. Noninvasive detection and differentiation of gastric malignancy using cell-free DNA biomarkers.2026Journal of advanced research免费全文
  2. Effect of sevoflurane-based or propofol-based anesthesia on acute kidney injury after surgery for gastric cancer: a retrospective propensity score-matched analysis.2025BMC anesthesiology免费全文
  3. Predictive value of 18F-FDG PET/CT metabolic parameters for gastric cancer patients' microsatellite instability status.2025BMC cancer免费全文
  4. The prealbumin-CD19+ index predicts surgical survival in patients with GC.2025BMC cancer免费全文
  5. Sedated and unsedated gastroscopy has no influence on the outcomes of patients with gastric cancer: a retrospective study.2025BMC cancer免费全文
  6. Enhanced recovery after gastrectomy: updated Meta-analysis of 27 randomized trials (2018-2025).2025BMC surgery免费全文
  7. A Comprehensive Analysis of the Clinical Significance and Underlying Oncogenic Roles of Specific MMPs in Gastric Carcinoma Reveals their Potential Roles in Prognosis and Therapy.2025Current molecular medicine免费全文
  8. Skeletal muscle index combined with IgM predicts prognosis in gastric cancer patients who underwent surgery.2025Frontiers in immunology免费全文
  9. Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China.2025Future oncology (London, England)免费全文
  10. Comparison of Short-Term Outcomes of Robot-Assisted Distal Gastrectomy Using the KangDuo Surgical Robot-01 System and Laparoscopic Gastrectomy.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  11. Study on the Safety and Effectiveness of Using Modified Tubular Stomach for Sideoverlap Anastomosis in Laparoscopic Proximal Gastrectomy.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  12. Effects of enhanced recovery after surgery nursing combined with early enteral nutrition on Gastrointestinal function recovery after radical gastrectomy.2025Langenbeck's archives of surgeryRCT免费全文
  13. A Polysaccharide-Based Fluorescent Polymer Carrier for Natural Product Delivery and Gastric Cancer Inhibition.2025Luminescence : the journal of biological and chemical luminescence
  14. Metabolic and aging related gene risk score for therapeutic stratification and precision oncology in gastric cancer.2025Medicine免费全文
  15. Nutritional Risk Index (NRI) predicts the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors (PD-1/PD-L1).2025Medicine免费全文
  16. A large histological images dataset of gastric cancer with tumour microenvironment annotation for AI.2025Scientific data免费全文
  17. LRP12 promotes gastric cancer progression through AKT/mTOR signaling and M2 macrophage-mediated immunosuppression.2025Scientific reports免费全文
  18. Integrating psychological and dietary care for patients with advanced gastric cancer undergoing chemotherapy: a randomized controlled trial.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  19. Clinical application of the KangDuo-Surgical Robot-01 in distal gastrectomy for gastric cancer.2025Updates in surgery
  20. Pescadillo ribosomal biogenesis factor 1 and programmed death-ligand 1 in gastric and head and neck squamous cell carcinoma.2025World journal of gastroenterology免费全文
  21. Machine learning-based reconstruction of prognostic staging for gastric cancer patients with different differentiation grades: A multicenter retrospective study.2025World journal of gastroenterology免费全文
  22. Integrin β5, a noninvasive diagnostic biomarker, is associated with unfavorable prognosis and immunotherapy efficacy in gastric cancer.2024BMC gastroenterology免费全文
  23. Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor.2024Cancer medicine免费全文
  24. EIF2S2 transcriptionally upregulates HIF1α to promote gastric cancer progression via activating PI3K/AKT/mTOR pathway.2024Carcinogenesis
  25. A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer.2024Current gene therapy
  26. Preoperative glucose-to-lymphocyte ratio predicts survival in cancer.2024Frontiers in endocrinology免费全文
  27. Eco-friendly green synthesis of N‑pyrazole amino chitosan using PEG-400 as an anticancer agent against gastric cancer cells via inhibiting EGFR.2024In vitro cellular & developmental biology. Animal
  28. Normalization weighted combination scores re-evaluate TNM staging of gastric cancer: a retrospective cohort study based on a multicenter database.2024International journal of surgery (London, England)免费全文
  29. Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer.2024Investigational new drugs免费全文
  30. CD3+/CD4+ cells combined with myosteatosis predict the prognosis in patients who underwent gastric cancer surgery.2024Journal of cachexia, sarcopenia and muscle免费全文
  31. Pan-cancer analysis of SERPINE1 with a concentration on immune therapeutic and prognostic in gastric cancer.2024Journal of cellular and molecular medicine免费全文
  32. Overall survival prediction of gastric cancer using the gene signature of CT-detected extramural venous invasion combined with M2 macrophages infiltration.2024Journal of translational medicine免费全文
  33. Geriatric nutritional risk index predicts the prognosis of gastric cancer patients treated with immune checkpoint inhibitors.2024Medicine免费全文
  34. EIF4A3-induced circle RNA_ 0001860 promotes growth, invasion, and immune evasion of gastric cancer cells through the miR-618/HMGA2 axis.2024Neoplasma
  35. Prediction of surgical benefit in gastric cancer patients with peritoneal metastasis treated with hyperthermic intraperitoneal chemotherapy.2024Updates in surgery免费全文
  36. Machine learning algorithms able to predict the prognosis of gastric cancer patients treated with immune checkpoint inhibitors.2024World journal of gastroenterology免费全文
  37. Development and validation of a prognostic immunoinflammatory index for patients with gastric cancer.2024World journal of gastroenterology免费全文
  38. Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor.2024World journal of gastroenterology免费全文
  39. Letter to the editor on"Prognostic significance of preoperative tumor markers combined with controlling nutritional status score in gastric cancer".2023Asian journal of surgery
  40. Development and Validation of Tumor Marker Indices in Advanced Gastric Cancer Patients.2023Cancer control : journal of the Moffitt Cancer Center免费全文
  41. Prognostic importance of the preoperative New-Naples prognostic score for patients with gastric cancer.2023Cancer medicine免费全文
  42. Prediction model based on radiomics and clinical features for preoperative lymphovascular invasion in gastric cancer patients.2023Future oncology (London, England)
  43. A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy.2023Journal of cancer research and clinical oncology免费全文
  44. The prognostic marker elastin correlates with epithelial-mesenchymal transition and vimentin-positive fibroblasts in gastric cancer.2023The journal of pathology. Clinical research免费全文
  45. Cancer-associated fibroblast expression of glutamine fructose-6-phosphate aminotransferase 2 (GFPT2) is a prognostic marker in gastric cancer.2023The journal of pathology. Clinical research免费全文
  46. Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer.2022BMC cancer免费全文
  47. The Survival Relationship between Preoperative Inflammation Markers and Patients with Special Pathological Types of Gastric Cancer.2022Canadian journal of gastroenterology & hepatology免费全文
  48. FSIP1 Is Associated with Poor Prognosis and Can Be Used to Construct a Prognostic Model in Gastric Cancer.2022Disease markers免费全文
  49. Evaluation of Immune Infiltration Based on Image Plus Helps Predict the Prognosis of Stage III Gastric Cancer Patients with Significantly Different Outcomes in Northeastern China.2022Disease markers免费全文
  50. Development and validation of a necroptosis-related gene prognostic score to predict prognosis and efficiency of immunotherapy in gastric cancer.2022Frontiers in immunology免费全文
  51. Laparoscopic versus open gastrectomy for gastric cancer: A systematic review and meta-analysis of randomized controlled trials.2022International journal of surgery (London, England)
  52. Development and validation of an individual alternative splicing prognostic signature in gastric cancer.2021Aging免费全文
  53. The landscape of alternative splicing reveals novel events associated with tumorigenesis and the immune microenvironment in gastric cancer.2021Aging免费全文
  54. Proximal gastrectomy with gastric tube reconstruction or jejunal interposition reconstruction in upper-third gastric cancer: which offers better short-term surgical outcomes?2021BMC surgery免费全文
  55. Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component.2021BioMed research international免费全文
  56. The Ratio of the Hemoglobin to Red Cell Distribution Width Combined with the Ratio of Platelets to Lymphocytes Can Predict the Survival of Patients with Gastric Cancer Liver Metastasis.2021BioMed research international免费全文
  57. Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine.2021Cancer chemotherapy and pharmacology
  58. Prognostic significance of serum inflammation indexes in different Lauren classification of gastric cancer.2021Cancer medicine免费全文
  59. ELF3-AS1 contributes to gastric cancer progression by binding to hnRNPK and induces thrombocytosis in peripheral blood.2021Cancer science免费全文
  60. Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer.2021Frontiers in immunology免费全文
  61. Comprehensive Characterization of RNA Processing Factors in Gastric Cancer Identifies a Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses.2021Frontiers in immunology免费全文
  62. Serum CD4 Is Associated with the Infiltration of CD4+T Cells in the Tumor Microenvironment of Gastric Cancer.2021Journal of immunology research免费全文
  63. A novel long noncoding RNA, TMEM92-AS1, promotes gastric cancer progression by binding to YBX1 to mediate CCL5.2021Molecular oncology免费全文
  64. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.2021Pathology oncology research : POR免费全文
  65. eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.2021Pathology, research and practice
  66. Application value of hand-sewn anastomosis in totally laparoscopic total gastrectomy for gastric cancer.2021World journal of surgical oncology免费全文
中文论文(未计入)1
  1. [Exploration of gasless laparoscopic gastric cancer surgery].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)53
  1. A Clinical Study for Comparison of the Effects Between Gasless Laparoscopy and Conventional Laparoscopy for Distal Gastric Cancer状态不明NCT05495217牵头方(推断)不分期2021-12 启动
  2. Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer状态不明NCT03237507牵头方(推断)2017-07 启动
  3. Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer已终止NCT01665274牵头方(推断)II期2013-09 启动
  4. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer正在招募NCT06731478研究中心III期2025-02 启动
  5. Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma正在招募NCT07102901研究中心II期2025-09 启动
  6. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer正在招募NCT06901531研究中心III期2025-05 启动
  7. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors正在招募NCT07066657研究中心I期2025-07 启动
  8. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer正在招募NCT07127822研究中心II期2025-12 启动
  9. A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma正在招募NCT07023315研究中心III期2025-08 启动
  10. A Phase 2 Clinical Study of ABSK061 and ABSK043正在招募NCT06632262研究中心II期2024-11 启动
  11. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  12. A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors正在招募NCT06783569研究中心I期2024-12 启动
  13. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy正在招募NCT06221748研究中心II/III期2024-02 启动
  14. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread正在招募NCT06324357研究中心I/II期2024-06 启动
  15. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  16. To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer正在招募NCT06504732研究中心II/III期2024-08 启动
  17. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT06155383研究中心II期2023-11 启动
  18. Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma正在招募NCT05918094研究中心III期2023-04 启动
  19. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors正在招募NCT04900818研究中心I期2021-06 启动
  20. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)进行中,不再招募NCT06710132研究中心I/II期2025-01 启动
  21. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  22. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.进行中,不再招募NCT06116136研究中心I/II期2024-08 启动
  23. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors进行中,不再招募NCT06257264研究中心I期2024-03 启动
  24. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China已完成NCT06585501研究中心2024-08 启动
  25. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma已终止NCT06206278研究中心II期2023-10 启动
  26. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  27. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  28. Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)进行中,不再招募NCT05382364研究中心I期2022-06 启动
  29. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  30. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs已完成NCT04852679研究中心III期2021-05 启动
  31. A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction已完成NCT04661150研究中心II期2021-03 启动
  32. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)进行中,不再招募NCT04704934研究中心III期2021-05 启动
  33. Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial状态不明NCT04744649研究中心II期2021-03 启动
  34. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  35. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations状态不明NCT05019794研究中心II期2020-05 启动
  36. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  37. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors已完成NCT04400383研究中心I期2020-06 启动
  38. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  39. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  40. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  41. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  42. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)已完成NCT03615326研究中心III期2018-10 启动
  43. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动
  44. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma已完成NCT03469557研究中心II期2017-07 启动
  45. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer已完成NCT02898077研究中心III期2017-03 启动
  46. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)已终止NCT03019588研究中心III期2017-02 启动
  47. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  48. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2状态不明NCT02356276研究中心III期2015-05 启动
  49. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动
  50. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer已完成NCT01774786研究中心III期2013-06 启动
  51. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动
  52. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)状态不明NCT01609309研究中心III期2012-09 启动
  53. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer已终止NCT01641939研究中心II/III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 156 篇,占 0.7%。

牵头论文
156
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
69
由其他机构牵头
每年牵头的论文数
2021: 222220212022: 232320222023: 232320232024: 373720242025: 47472025

哈尔滨有 4 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 69

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
    分期
    II/III期
    开始
    2026-01
    发布
    登记号
    NCT07063745

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、北京、南宁、南昌、厦门、哈尔滨、广州、成都、杭州、武汉、沈阳、福州、长沙

  2. 正在招募
    Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
    分期
    III期
    开始
    2026-01
    发布
    登记号
    NCT07195695

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 26 家列出的医院为研究中心上海、临沂、北京、南京、南昌、台州、哈尔滨、天津、广州、徐州、成都、扬州、杭州、武汉、济南、石家庄、苏州、郑州、长春、长沙

  3. 正在招募
    A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
    分期
    I/II期
    开始
    2026-03
    发布
    登记号
    NCT07227025

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、哈尔滨、广州

  4. 正在招募
    A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
    分期
    I/II期
    开始
    2026-01
    发布
    登记号
    NCT07227597

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南昌、台州、哈尔滨、广州、成都、杭州、江门、福州

  5. 正在招募
    A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
    分期
    II期
    开始
    2026-02
    发布
    登记号
    NCT07253142

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、南宁、合肥、哈尔滨、广州、徐州、新乡、武汉、福州

  6. 正在招募
    First in Human Study of SIM0610 in Solid Tumors
    分期
    I期
    开始
    2026-01
    发布
    登记号
    NCT07348211

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、哈尔滨、沈阳、重庆

  7. 正在招募
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
    分期
    I/II期
    开始
    2026-02
    发布
    登记号
    NCT07367529

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、中山、北京、南京、南宁、南昌、台州、哈尔滨、天津、太原、广州、成都、扬州、杭州、武汉、西安、长沙

  8. 正在招募
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    分期
    III期
    开始
    2026-04
    发布
    登记号
    NCT07416474

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 66 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、桂林、武汉、江门、沈阳、洛阳、济南、深圳、温州、烟台、珠海、石家庄、福州、苏州、襄阳、郑州、重庆、银川、长春、长沙、青岛

  9. 正在招募
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
    分期
    III期
    开始
    2026-04
    发布
    登记号
    NCT07472517

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、哈尔滨、天津、太原、宁波、广州、徐州、成都、扬州、杭州、武汉、济南、温州、福州、蚌埠、襄阳、郑州、长沙

  10. 正在招募
    A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
    分期
    II期
    开始
    2026-07
    发布
    登记号
    NCT07622186

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 24 家列出的医院为研究中心北京、南京、南宁、南昌、厦门、哈尔滨、天津、太原、广州、成都、昆明、杭州、桂林、沈阳、济南、福州、襄阳、西安、郑州、重庆、长春、长沙

  11. 正在招募
    A Study of DS-3939a in Participants With Solid Tumors
    分期
    I/II期
    开始
    2026-10
    发布
    登记号
    NCT07739966

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、台州、哈尔滨、天津、广州、杭州、武汉、济南、郑州、长春、长沙

  12. 正在招募
    A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
    分期
    I/II期
    开始
    2026-10
    发布
    登记号
    NCT07843940

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、哈尔滨、成都

  13. 正在招募
    A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    分期
    II期
    开始
    2025-01
    发布
    登记号
    NCT06568939

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心临沂、乌鲁木齐、南宁、南昌、哈尔滨、武汉、福州、西安、郑州

  14. 正在招募
    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
    分期
    III期
    开始
    2025-02
    发布
    登记号
    NCT06712355

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南昌、台州、合肥、哈尔滨、太原、广州、扬州、新乡、杭州、武汉、汕头、济南、温州、石家庄、福州、苏州、蚌埠、襄阳、郑州、重庆、长春

  15. 正在招募
    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
    分期
    III期
    开始
    2025-07
    发布
    登记号
    NCT06758401

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、哈尔滨、天津、常州、广州、徐州、成都、杭州、武汉、洛阳、济南、温州、福州、西安、郑州、长沙

  16. 正在招募
    A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2025-10
    发布
    登记号
    NCT06793215

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南昌、南通、合肥、哈尔滨、广州、成都、昆明、杭州、武汉、汕头、济南、蚌埠、长沙

  17. 正在招募
    Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
    分期
    III期
    开始
    2025-04
    发布
    登记号
    NCT06801834

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南京、南昌、厦门、哈尔滨、天津、太原、广州、成都、扬州、新乡、杭州、武汉、深圳、福州、西安、郑州、重庆、长春

  18. 正在招募
    A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
    分期
    I期
    开始
    2025-02
    发布
    登记号
    NCT06839105

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南昌、哈尔滨、广州、昆明、杭州、武汉、沈阳、洛阳、福州、长春、长沙

  19. 正在招募
    Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
    分期
    未注明
    开始
    2025-04
    发布
    登记号
    NCT06862869

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、兰州、北京、南京、南昌、南通、台州、合肥、哈尔滨、大连、太原、广州、成都、无锡、杭州、武汉、江门、济南、深圳、湛江、石家庄、福州、西安、遵义、重庆、银川、长沙

  20. 正在招募
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    分期
    III期
    开始
    2025-04
    发布
    登记号
    NCT06875310

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、广州、成都、扬州、新乡、杭州、武汉、汕头、沈阳、济南、深圳、石家庄、福州、苏州、蚌埠、重庆、长春、长沙

  21. 正在招募
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2025-03
    发布
    登记号
    NCT06890598

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、佛山、北京、南宁、台州、哈尔滨、天津、安阳、广州、成都、杭州、武汉、汕头、洛阳、济南、深圳、苏州、西安、重庆、长沙

  22. 正在招募
    Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
    分期
    III期
    开始
    2025-10
    发布
    登记号
    NCT06899126

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南昌、合肥、哈尔滨、天津、太原、广州、成都、杭州、武汉、沈阳、济南、襄阳、郑州、重庆、长春、长沙

  23. 正在招募
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    分期
    II期
    开始
    2025-06
    发布
    登记号
    NCT06962865

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心临沂、北京、哈尔滨、天津、太原、广州、成都、昆明、杭州、桂林、武汉、济南、温州、烟台、石家庄、福州、襄阳、郑州、重庆、长春、长沙

  24. 正在招募
    A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
    分期
    III期
    开始
    2025-06
    发布
    登记号
    NCT07010263

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、哈尔滨、天津、太原、安阳、广州、新乡、武汉、江门、沈阳、济南、温州、石家庄、福州、西安、遵义、郑州、重庆、银川、长春、长沙

  25. 正在招募
    A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
    分期
    未注明
    开始
    2025-12
    发布
    登记号
    NCT07143045

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 24 家列出的医院为研究中心佛山、南京、南宁、南昌、厦门、合肥、哈尔滨、天津、太原、广州、成都、扬州、昆明、武汉、沈阳、深圳、福州、郑州、重庆、长春、长沙、青岛

  26. 正在招募
    A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
    分期
    III期
    开始
    2025-09
    发布
    登记号
    NCT07144280

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南京、南宁、南昌、台州、合肥、哈尔滨、常州、广州、徐州、成都、杭州、武汉、济南、福州、西安、郑州、重庆、长沙

  27. 正在招募
    A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
    分期
    II期
    开始
    2025-09
    发布
    登记号
    NCT07164170

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、北京、南京、南宁、合肥、哈尔滨、广州、成都、武汉、沈阳、福州、西安、郑州

  28. 正在招募
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    分期
    I/II期
    开始
    2025-09
    发布
    登记号
    NCT07169994

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、南京、南昌、合肥、哈尔滨、天津、太原、安阳、广州、成都、沈阳、洛阳、福州、襄阳

  29. 正在招募
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07182682

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 47 家列出的医院为研究中心上海、北京、南京、南宁、台州、合肥、哈尔滨、天津、太原、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、福州、西安、郑州、长春、长沙

  30. 正在招募
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07185997

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、临沂、佛山、北京、南京、南宁、南昌、南通、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、新乡、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、潍坊、石家庄、福州、郑州、重庆、长沙、青岛

  31. 正在招募
    A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2025-11
    发布
    登记号
    NCT07217301

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、徐州、成都、新乡、昆明、杭州、沈阳、泸州、济南、温州、石家庄、福州、西安、郑州、重庆、长沙

  32. 正在招募
    A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
    分期
    III期
    开始
    2025-11
    发布
    登记号
    NCT07218146

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、广州、成都、杭州、武汉、济南、石家庄、福州、西安、郑州、长春、长沙

  33. 正在招募
    A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
    分期
    I期
    开始
    2024-01
    发布
    登记号
    NCT06179069

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、广州、成都、武汉、沈阳、西安、郑州、长沙

  34. 正在招募
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06203210

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、哈尔滨、天津、成都、杭州、武汉、沈阳、济南、烟台、襄阳、郑州、重庆、长沙

  35. 正在招募
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06345729

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、无锡、杭州、武汉、济南、温州、福州、苏州、西安、郑州、重庆、长沙

  36. 正在招募
    A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
    分期
    I期
    开始
    2024-04
    发布
    登记号
    NCT06403735

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、南昌、哈尔滨、昆明

  37. 正在招募
    JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
    分期
    III期
    开始
    2024-08
    发布
    登记号
    NCT06416410

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南京、南宁、台州、哈尔滨、天津、太原、广州、成都、无锡、杭州、武汉、沈阳、济南、深圳、福州、西安、郑州、长沙、青岛

  38. 正在招募
    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
    分期
    III期
    开始
    2024-06
    发布
    登记号
    NCT06422143

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、厦门、台州、哈尔滨、广州、成都、扬州、杭州、武汉、温州、福州、郑州、长春、长沙

  39. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    发布
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  40. 正在招募
    A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    分期
    III期
    开始
    2024-08
    发布
    登记号
    NCT06452277

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、临沂、北京、南京、厦门、台州、哈尔滨、广州、成都、杭州、武汉、济南、福州、长春、长沙

  41. 正在招募
    A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
    分期
    II期
    开始
    2024-08
    发布
    登记号
    NCT06496490

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、佛山、北京、南宁、南昌、哈尔滨、天津、广州、成都、江门、福州、西安、遵义、郑州、长春、长沙

  42. 正在招募
    A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
    分期
    III期
    开始
    2024-10
    发布
    登记号
    NCT06561386

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南宁、南昌、台州、哈尔滨、天津、太原、广州、成都、新乡、杭州、沈阳、济南、福州、重庆、长沙

  43. 正在招募
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06632262

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、济南、石家庄、襄阳、贵阳、郑州

  44. 正在招募
    A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06668103

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、哈尔滨、武汉、长春

  45. 正在招募
    Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
    分期
    I/II期
    开始
    2024-11
    发布
    登记号
    NCT07433283

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、成都、海口、福州、郑州、重庆、长沙

  46. 正在招募
    A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
    分期
    I/II期
    开始
    2023-06
    发布
    登记号
    NCT05789082

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、哈尔滨、长沙

  47. 正在招募
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
    分期
    III期
    开始
    2023-11
    发布
    登记号
    NCT05920356

    年龄 18 岁 至 100 岁(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、南通、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、成都、昆明、杭州、武汉、汕头、洛阳、济南、潍坊、石家庄、福州、蚌埠、襄阳、西安、郑州、重庆、长春、长沙

  48. 正在招募
    A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
    分期
    II期
    开始
    2023-12
    发布
    登记号
    NCT06010329

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南京、南昌、哈尔滨、广州、成都、杭州、武汉、济南、郑州

  49. 正在招募
    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
    分期
    III期
    开始
    2023-11
    发布
    登记号
    NCT06095583

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、北京、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、成都、杭州、武汉、沈阳、济南、深圳、郑州、重庆、银川、长春、长沙、青岛

  50. 正在招募
    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
    分期
    III期
    开始
    2023-12
    发布
    登记号
    NCT06119581

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、台州、哈尔滨、天津、宜昌、常州、广州、成都、杭州、武汉、济南、海口、湛江、福州、襄阳、西安、长沙

  51. 正在招募
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    分期
    III期
    开始
    2023-12
    发布
    登记号
    NCT06170788

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南昌、厦门、台州、合肥、哈尔滨、广州、徐州、成都、无锡、杭州、武汉、济南、湛江、石家庄、福州、襄阳、郑州、长沙

  52. 正在招募
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    分期
    III期
    开始
    2022-03
    发布
    登记号
    NCT04928846

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南宁、南昌、南通、厦门、台州、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、昆明、杭州、武汉、汕头、沈阳、济南、湛江、石家庄、福州、西安、郑州、重庆、长春、长沙

  53. 正在招募
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
    分期
    II期
    开始
    2022-09
    发布
    登记号
    NCT05168566

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、北京、南京、哈尔滨、广州、成都、杭州、武汉、沈阳、蚌埠、郑州、长春、长沙

  54. 正在招募
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
    分期
    I/II期
    开始
    2022-04
    发布
    登记号
    NCT05288205

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、临沂、北京、厦门、合肥、呼和浩特、哈尔滨、广州、武汉、沈阳、济南、深圳、福州、郑州、长沙

  55. 正在招募
    A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
    分期
    II期
    开始
    2022-11
    发布
    登记号
    NCT05498428

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、哈尔滨、天津、广州、成都、杭州、武汉、温州、烟台、石家庄、西安

  56. 正在招募
    Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
    分期
    I期
    开始
    2021-07
    发布
    登记号
    NCT04886804

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、南宁、厦门、哈尔滨、广州、杭州、武汉、福州、郑州、长春

  57. 正在招募
    A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
    分期
    I期
    开始
    2021-08
    发布
    登记号
    NCT04913285

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、临沂、哈尔滨

  58. 正在招募
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    分期
    I/II期
    开始
    2021-09
    发布
    登记号
    NCT04930432

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 56 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、南通、厦门、台州、合肥、哈尔滨、大连、天津、太原、广州、徐州、成都、昆明、杭州、武汉、汕头、沈阳、济南、深圳、温州、潍坊、烟台、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长春、长沙、青岛

  59. 正在招募
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    分期
    I/II期
    开始
    2021-11
    发布
    登记号
    NCT05024214

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、北京、哈尔滨、大连、天津、太原、广州、昆明、杭州、沈阳、珠海、福州、蚌埠、郑州、长春

  60. 正在招募
    First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
    分期
    I/II期
    开始
    2021-10
    发布
    登记号
    NCT05099172

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南京、台州、哈尔滨、成都、杭州、济南、福州、长沙

  61. 正在招募
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
    分期
    II/III期
    开始
    2020-12
    发布
    登记号
    NCT04613596

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 30 家列出的医院为研究中心上海、临沂、北京、南宁、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、杭州、武汉、沈阳、济南、深圳、石家庄、福州、蚌埠、西安、郑州、重庆、长春、长沙

  62. 正在招募
    Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
    分期
    I/II期
    开始
    2019-07
    发布
    登记号
    NCT04270591

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、济南、石家庄、郑州、长春、长沙

  63. 即将招募
    A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
    分期
    I期
    开始
    2026-06
    发布
    登记号
    NCT07550842

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、台州、哈尔滨、常州、武汉、沈阳、郑州

  64. 即将招募
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    分期
    II期
    开始
    2026-06
    发布
    登记号
    NCT07623642

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、哈尔滨

  65. 即将招募
    A Phase 2 Study of ABSK043 Combined With Osimertinib
    分期
    II期
    开始
    2026-08
    发布
    登记号
    NCT07710612

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、哈尔滨、太原、广州、杭州、武汉、沈阳

  66. 即将招募
    Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    分期
    I期
    开始
    2026-11
    发布
    登记号
    NCT07912268

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、南昌、哈尔滨、福州、长沙

  67. 即将招募
    Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
    分期
    II期
    开始
    2025-03
    发布
    登记号
    NCT06885840

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心佛山、兰州、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、济南、西安、郑州、长春、长沙

  68. 即将招募
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    分期
    III期
    开始
    2023-05
    发布
    登记号
    NCT05767892

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、北京、南京、南昌、厦门、台州、合肥、呼和浩特、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长沙、青岛

  69. 即将招募
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
    分期
    III期
    开始
    2023-11
    发布
    登记号
    NCT05990127

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、合肥、哈尔滨、天津、太原、广州、徐州、成都、新乡、昆明、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、银川、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科病理/检验科放疗科影像/核医学科
牵头的论文156
  1. Prognostic Value of Multiparameter Biomarkers in Pleural Effusion of Patients With Non-small Cell Lung Cancer for Predicting Survival Outcomes: A Prospective Cohort Study.2026American journal of clinical oncology
  2. A positive feedback loop between SERPINH1 and MMP-9/TGF-β1 promotes lung adenocarcinoma progression.2026Cell death and differentiation
  3. Real-world effectiveness and safety of treatment strategies for unresectable, driver-negative Stage III NSCLC: A retrospective multicentre study.2026International journal of cancer
  4. Cost-effectiveness analysis of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer.2026Journal of chemotherapy (Florence, Italy)
  5. Pericardial Fat and Primary Tumor Radiomics for Predicting Occult N2 Disease and Survival in Clinical Stage I Non-Small Cell Lung Cancer: Multicenter Study and Biologic Correlation.2025AJR. American journal of roentgenology
  6. Targeting piRNA-137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo Cholesterol Biosynthesis in Lung Adenocarcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  7. Integrin β8 Facilitates Macrophage Infiltration and Polarization by Regulating CCL5 to Promote LUAD Progression.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  8. Implementing liquid biopsy NGS in stage III/IV NSCLC: clinical utility assessment from a real-world Chinese cohort.2025BMC cancer免费全文
  9. A CT-based radiomics nomogram incorporating adipose tissue to differentiate invasive adenocarcinomas among part-solid pulmonary nodules.2025BMC cancer免费全文
  10. Deep learning radiomics and mediastinal adipose tissue-based nomogram for preoperative prediction of postoperative‌ brain metastasis risk in non-small cell lung cancer.2025BMC cancer免费全文
  11. Disease burden of lung cancer attributable to metabolic and behavioral risks in China and globally from 1990 to 2021.2025BMC public health免费全文
  12. m6A-modified EHD1 controls PD-L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma.2025Cancer communications (London, England)免费全文
  13. Development and validation of nomograms to predict brain metastasis-free survival in lung and breast cancer.2025Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  14. MS4A1 regulates M1-polarized tumor-associated macrophage infiltration, angiogenesis, and cancer progression through the HIPPO pathway in lung adenocarcinoma.2025Cancer immunology, immunotherapy : CII免费全文
  15. Multimodal Deep Learning Integrating Tumor Radiomics and Mediastinal Adiposity Improves Survival Prediction in Non-Small Cell Lung Cancer: A Prognostic Modeling Study.2025Cancer medicine免费全文
  16. Therapeutic efficacy of TMTP1-modified EVs in overcoming bone metastasis and immune resistance in PIK3CA mutant NSCLC.2025Cell death & disease免费全文
  17. M6A -mediated lncRNA SCIRT stability promotes NSCLC progression through binding to SFPQ and activating the PI3K/Akt pathway.2025Cellular and molecular life sciences : CMLS免费全文
  18. Application of random survival forest to establish a nomogram combining clinlabomics-score and clinical data for predicting brain metastasis in primary lung cancer.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico免费全文
  19. Correlation between radiologic feature and spread through air space in lung solid adenocarcinoma 30.0 mm or less in maximum diameter.2025Clinical imaging
  20. Prediction of PD-L1 expression in NSCLC patients using PET/CT radiomics and prognostic modelling for immunotherapy in PD-L1-positive NSCLC patients.2025Clinical radiology
  21. Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer.2025Critical reviews in oncology/hematology
  22. MFAP5 Strengthened the Stem Cell Features of Non-small Cell Lung Cancer Cells by Regulating the FBW/Sox9 Axis.2025Current pharmaceutical biotechnology
  23. Opsin3 regulates cell proliferation, migration, and apoptosis in lung adenocarcinoma via GPX3 pathway.2025European journal of medical research免费全文
  24. Assessing the genetic estimates of the association between plasma caffeine and cancer risk through Mendelian randomization.2025European journal of nutrition
  25. Deep learning model using CT images for longitudinal prediction of benign and malignant ground-glass nodules.2025European journal of radiology
  26. Post-hoc analysis of real-world retrospective study on neoadjuvant chemotherapy combined with immunotherapy for stage I-III non-small cell lung cancer.2025Frontiers in immunology免费全文
  27. Advancements in extensive-stage small cell lung cancer therapy: from molecular profiling to the advent of precision oncology.2025Frontiers in immunology免费全文
  28. The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy.2025Frontiers in immunology免费全文
  29. A comprehensive prognostic and immunological implications of Gremlin 1 in lung adenocarcinoma.2025Frontiers in immunology免费全文
  30. Serum sphingosine-1-phosphate levels are associated with brain metastasis in EGFR-mutant lung adenocarcinoma.2025Future oncology (London, England)免费全文
  31. The role of exosomal PD-L1 in NSCLC immunotherapy.2025Immunotherapy免费全文
  32. RUNX1 promotes NSCLC progression by ACP5/SMAD3-mediated M2 macrophage polarization.2025Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  33. Development of a machine learning-based prognostic model for survival prediction in patients with lung cancer brain metastases using multicenter clinical data.2025International journal of medical informatics
  34. Molecular characterization of breast cancer and multiple primary malignancies: the latest application using unmarked quantitative proteomics.2025International journal of surgery (London, England)免费全文
  35. Peptide YY fragment PYY1-36 disrupts mitochondrial biogenesis via RBM43-dependent PGC-1α translation inhibition.2025Investigational new drugs免费全文
  36. Predictive classification of lung cancer pathological based on PET/CT radiomics.2025Japanese journal of radiology
  37. RBM10 deficiency promotes brain metastasis by modulating sphingolipid metabolism in a BBB model of EGFR mutant lung adenocarcinoma.2025Journal of experimental & clinical cancer research : CR免费全文
  38. Overcoming acquired immunotherapy resistance in non-small cell lung cancer using ginsenoside Rb1-loaded, peptide-enhanced exosome delivery systems.2025Journal of nanobiotechnology免费全文
  39. RBM15 recruits myeloid-derived suppressor cells via the m6A-IGF2BP3/CBR3-AS1/miR-409-3p/CXCL1 axis, facilitating radioresistance in non-small-cell lung cancer.2025Journal of translational medicine免费全文
  40. Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges.2025Lung cancer (Amsterdam, Netherlands)
  41. Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models.2025Molecular cancer therapeutics免费全文
  42. 19F MR Imaging of Dule Lung Cancer Models with Two Administration Methods of PFC Nanoparticles.2025Molecular imaging and biology
  43. RFX2-BNIP3 axis-driven adaptive mitophagy promotes resistance to ACK1-targeted therapy in non-small cell lung cancer.2025Oncogene
  44. RNA‑binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125.2025Oncology reports免费全文
  45. Dual biomarkers CT-based deep learning model incorporating intrathoracic fat for discriminating benign and malignant pulmonary nodules in multi-center cohorts.2025Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
  46. Landscape of the intratumoral microbiota acting on the tumor immune microenvironment in LUAD and LUSC.2025Physiological genomics
  47. CT Predictors of Angiolymphatic Invasion in Non-Small Cell Lung Cancer 30 mm or Smaller.2025Radiology
  48. ZNF184-mediated transcriptional activation of SAE1 drives the cell cycle entry and immune evasion in non-small cell lung cancer.2025Respiratory research免费全文
  49. In vivo self-assembled bispecific fluorescence probe for early detection of bladder cancer and metastasis.2025Science bulletin
  50. Efficacy and toxicity of stereotactic radiotherapy combined with third-generation EGFR-TKIs and immunotherapy in patients with brain metastases from non-small cell lung cancer.2025Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]免费全文
  51. Comprehensive profiling of T-cell exhaustion signatures and establishment of a prognostic model in lung adenocarcinoma through integrated RNA-sequencing analysis.2025Technology and health care : official journal of the European Society for Engineering and Medicine
  52. m6A-Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  53. Ubiquitin-Specific Protease 22 Plays a Key Role in Increasing Extracellular Vesicle Secretion and Regulating Cell Motility of Lung Adenocarcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  54. Clinical significance of the combined systemic immune-inflammatory index and prognostic nutritional index in predicting the prognosis of patients with extensive-stage small-cell lung cancer receiving immune-combination chemotherapy.2024BMC cancer免费全文
  55. Deep learning-based characterization of pathological subtypes in lung invasive adenocarcinoma utilizing 18F-deoxyglucose positron emission tomography imaging.2024BMC cancer免费全文
  56. Development and validation of a preoperative CT‑based radiomics nomogram to differentiate tuberculosis granulomas from lung adenocarcinomas: an external validation study.2024BMC cancer免费全文
  57. Red blood cell distribution width is associated with sarcopenia risk in early-stage non-small cell lung cancer.2024BMC cancer免费全文
  58. FERMT1 promotes cell migration and invasion in non-small cell lung cancer via regulating PKP3-mediated activation of p38 MAPK signaling.2024BMC cancer免费全文
  59. Dexmedetomidine promotes necroptosis by upregulating PARP1 in non-small cell lung cancer.2024Biotechnology & genetic engineering reviews
  60. Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer.2024Cancer chemotherapy and pharmacology
  61. An Integrated Nomogram Combining Deep Learning and Radiomics for Predicting Malignancy of Pulmonary Nodules Using CT-Derived Nodules and Adipose Tissue: A Multicenter Study.2024Cancer medicine免费全文
  62. The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients.2024Cancer medicine免费全文
  63. A novel iTreg-related signature for prognostic prediction in lung adenocarcinoma.2024Cancer science免费全文
  64. Multi-scale and multi-view network for lung tumor segmentation.2024Computers in biology and medicine
  65. METnet: A novel deep learning model predicting MET dysregulation in non-small-cell lung cancer on computed tomography images.2024Computers in biology and medicine
  66. Predicting the Prognosis of Lung Cancer Patients Treated with Intensitymodulated Radiotherapy based on Radiomic Features.2024Current medical imaging
  67. MicroRNA-522-3p promotes brain metastasis in non-small cell lung cancer by targeting Tensin 1 and modulating blood-brain barrier permeability.2024Experimental cell research
  68. Preoperative glucose-to-lymphocyte ratio predicts survival in cancer.2024Frontiers in endocrinology免费全文
  69. Multimodal data deep learning method for predicting symptomatic pneumonitis caused by lung cancer radiotherapy combined with immunotherapy.2024Frontiers in immunology免费全文
  70. Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study.2024Frontiers in immunology免费全文
  71. Tumor-derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer.2024Frontiers in immunology免费全文
  72. Spatial tertiary lymphoid structures imply response to anti-PD-1 plus anlotinib in advanced non-small cell lung cancer.2024Immunology
  73. LncRNA HAR1A inhibits non-small cell lung cancer growth by downregulating c-MYC transcripts and facilitating its proteasomal degradation.2024International immunopharmacology
  74. Combination of the cuproptosis inducer disulfiram and anti‑PD‑L1 abolishes NSCLC resistance by ATP7B to regulate the HIF‑1 signaling pathway.2024International journal of molecular medicine免费全文
  75. Draw on advantages and avoid disadvantages: CT-derived individualized radiomic signature for predicting chemo-radiotherapy sensitivity in unresectable advanced non-small cell lung cancer.2024Journal of cancer research and clinical oncology免费全文
  76. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.2024Journal of cancer research and clinical oncology免费全文
  77. Safety of one 8.5-Fr pigtail catheter for postoperative continuous open gravity drainage after uniportal video-assisted thoracoscopic surgery pneumonectomy.2024Journal of cardiothoracic surgery免费全文
  78. Investigation of mediastinal lymph node dissection in clinical stage IA pure-solid non-small cell lung cancer patients.2024Journal of cardiothoracic surgery免费全文
  79. Radiotherapy combined with anti-PD-1 and TKI for primary cardiac angiosarcoma considering the joint assessment of TLSs and PD-L1: a case report.2024Journal of cardiothoracic surgery免费全文
  80. Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.2024Journal of immunotherapy (Hagerstown, Md. : 1997)
  81. An innovative electrohydrodynamics-driven SERS platform for molecular stratification and treatment monitoring of lung cancer.2024Journal of materials chemistry. B
  82. Sleep disturbance as a poor prognostic predictor in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A prospective study.2024Journal of psychosomatic research
  83. Dynamic analysis of predictive biomarkers for radiation therapy efficacy in non-small cell lung cancer patients by next-generation sequencing based on blood specimens.2024Pathology, research and practice
  84. SP1 undergoes phase separation and activates RGS20 expression through super-enhancers to promote lung adenocarcinoma progression.2024Proceedings of the National Academy of Sciences of the United States of America免费全文
  85. CT Predictors of Visceral Pleural Invasion in Patients with Non-Small Cell Lung Cancers 30 mm or Smaller.2024Radiology
  86. Influence of malnutrition according to the glim criteria on the chemotherapy toxicities in patients with advanced lung cancer.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  87. Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma.2024Thoracic cancer免费全文
  88. Prognostic factors in patients with first diagnosis of hepatocellular carcinoma presenting with pulmonary metastasis and construction of a clinical prediction model.2024Updates in surgery
  89. Development and validation of 18F-FDG PET/CT radiomics-based nomogram to predict visceral pleural invasion in solid lung adenocarcinoma.2023Annals of nuclear medicine
  90. The prediction of distant metastasis risk for male breast cancer patients based on an interpretable machine learning model.2023BMC medical informatics and decision making免费全文
  91. Sec61γ is a vital protein in the endoplasmic reticulum membrane promoting tumor metastasis and invasion in lung adenocarcinoma.2023British journal of cancer免费全文
  92. LINC00669 promotes lung adenocarcinoma growth by stimulating the Wnt/β-catenin signaling pathway.2023Cancer medicine免费全文
  93. M6A RNA methylation-mediated RMRP stability renders proliferation and progression of non-small cell lung cancer through regulating TGFBR1/SMAD2/SMAD3 pathway.2023Cell death and differentiation免费全文
  94. A Novel PRKAR1A::MET Fusion Dramatic Response to Crizotinib in a Patient with Unresectable Lung Cancer.2023Clinical lung cancer
  95. Preoperative small airway dysfunction is associated with skeletal muscle loss in early-stage non-small cell lung cancer.2023Clinical nutrition (Edinburgh, Scotland)
  96. Deep learning for predicting the risk of immune checkpoint inhibitor-related pneumonitis in lung cancer.2023Clinical radiologyRCT
  97. IGF2BP3 Worsens Lung Cancer through Modifying Long Non-coding RNA CERS6-AS1/microRNA-1202 Axis.2023Current medicinal chemistry
  98. miR-4732-3p prevents lung cancer progression via inhibition of the TBX15/TNFSF11 axis.2023Epigenomics
  99. Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients.2023European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  100. Establishment and validation of nomograms to predict survival probability of advanced malignant pleural mesothelioma based on the SEER database and a Chinese medical institution.2023Frontiers in endocrinology免费全文
  101. Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs.2023Immunopharmacology and immunotoxicology
  102. The significance of spread through air spaces in the prognostic assessment model of stage I lung adenocarcinoma and the exploration of its invasion mechanism.2023Journal of cancer research and clinical oncology免费全文
  103. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.2023Journal of chemotherapy (Florence, Italy)
  104. Predictive Value of Gene Databases in Discovering New Biomarkers and New Therapeutic Targets in Lung Cancer.2023Medicina (Kaunas, Lithuania)免费全文
  105. Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1.2023Molecular medicine (Cambridge, Mass.)免费全文
  106. The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy.2023Technology in cancer research & treatment免费全文
  107. Sevoflurane attenuates proliferative and migratory activity of lung cancer cells via mediating the microRNA-100-3p/sterol O-Acyltransferase 1 axis.2023The Chinese journal of physiology
  108. Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.2023The Journal of biological chemistry免费全文
  109. microRNA-651-5p affects the proliferation, migration, and invasion of lung cancer cells by regulating Calmodulin 2 expression.2023The clinical respiratory journal免费全文
  110. NIR-IIb fluorescence-image guided synergistic surgery/starvation/chemodynamic therapy: an innovative treatment paradigm for malignant non-small cell lung cancers.2023Theranostics免费全文
  111. Analysis between macrophage-related genes with prognosis and tumor microenvironment in non-small cell lung cancer.2023Yi chuan = Hereditas
  112. Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer.2022BMC cancer免费全文
  113. Preoperative PDW levels predict pulmonary metastasis in patients with hepatocellular carcinoma.2022BMC cancer免费全文
  114. Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma.2022Cancer immunology, immunotherapy : CII免费全文
  115. Surgical Trauma-induced CCL2 Upregulation Mediates Lung Cancer Progression by Promoting Treg Recruitment in Mice and Patients.2022Cancer investigation
  116. Long noncoding RNA CBR3-AS1 mediates tumorigenesis and radiosensitivity of non-small cell lung cancer through redox and DNA repair by CBR3-AS1 /miR-409-3p/SOD1 axis.2022Cancer letters
  117. TMEM139 prevents NSCLC metastasis by inhibiting lysosomal degradation of E-cadherin.2022Cancer science免费全文
  118. miR-596-3p suppresses brain metastasis of non-small cell lung cancer by modulating YAP1 and IL-8.2022Cell death & disease免费全文
  119. A novel EHD1/CD44/Hippo/SP1 positive feedback loop potentiates stemness and metastasis in lung adenocarcinoma.2022Clinical and translational medicine免费全文
  120. Prognostic Value of Combination of Controlling Nutritional Status and Tumor Marker in Patients with Radical Non-Small-Cell Lung Cancer.2022Disease markers免费全文
  121. CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma.2022Frontiers in immunology免费全文
  122. Long-term safety and efficacy of bisphosphonate therapy in advanced lung cancer with bone metastasis.2022Future oncology (London, England)
  123. Knockdown of LINC00511 decreased cisplatin resistance in non-small cell lung cancer by elevating miR-625 level to suppress the expression of leucine rich repeat containing eight volume-regulated anion channel subunit E.2022Human & experimental toxicology
  124. TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.2022International journal of biological sciences免费全文
  125. RNA-binding motif protein 10 represses tumor progression through the Wnt/β- catenin pathway in lung adenocarcinoma.2022International journal of biological sciences免费全文
  126. Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer.2022International journal of clinical practice免费全文
  127. Prognostic and Immunological Implications of FAM72A in Pan-Cancer and Functional Validations.2022International journal of molecular sciences免费全文
  128. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.2022JAMA network openRCT免费全文
  129. Technical aspects and early results of uniportal video-assisted thoracoscopic complex segmentectomy: a 30 case-series study.2022Journal of cardiothoracic surgery免费全文
  130. Characterization of the prognostic and diagnostic values of ALKBH family members in non-small cell lung cancer.2022Pathology, research and practice
  131. Radiomics combined with clinical features in distinguishing non-calcifying tuberculosis granuloma and lung adenocarcinoma in small pulmonary nodules.2022PeerJ免费全文
  132. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.2022Respiratory research免费全文
  133. Sarcopenia is an independent risk factor for depression in patients with advanced lung cancer.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  134. Patient-Generated Subjective Global Assessment (PG-SGA) predicts length of hospital stay in lung adenocarcinoma patients.2022The British journal of nutrition免费全文
  135. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.2021Aging免费全文
  136. Identification of downstream signaling cascades of ACK1 and prognostic classifiers in non-small cell lung cancer.2021Aging免费全文
  137. Knock-down of microRNA miR-556-5p increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via activating NLR family pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death.2021Bioengineered免费全文
  138. Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer.2021Bosnian journal of basic medical sciences免费全文
  139. High BASP1 Expression is Associated with Poor Prognosis and Promotes Tumor Progression in Human Lung Adenocarcinoma.2021Cancer investigation
  140. A feedback circuit comprising EHD1 and 14-3-3ζ sustains β-catenin/c-Myc-mediated aerobic glycolysis and proliferation in non-small cell lung cancer.2021Cancer letters
  141. Dynamic biomarkers indicate the immunological benefits provided by Ganoderma spore powder in post-operative breast and lung cancer patients.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoRCT
  142. Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials.2021European journal of clinical pharmacology
  143. PIGF and Flt-1 on the surface of macrophages induces the production of TGF-β1 by polarized tumor-associated macrophages to promote lung cancer angiogenesis.2021European journal of pharmacology
  144. The lncRNA ALMS1-IT1 may promote malignant progression of lung adenocarcinoma via AVL9-mediated activation of the cyclin-dependent kinase pathway.2021FEBS open bio免费全文
  145. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.2021Frontiers in immunology免费全文
  146. The Important Role of N6-methyladenosine RNA Modification in Non-Small Cell Lung Cancer.2021Genes免费全文
  147. Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients.2021International journal of clinical practice
  148. Stereotactic body radiation therapy for non-small cell lung cancer using the non-coplanar radiation of Cyberknife and Varian linac.2021Journal of X-ray science and technology
  149. High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis.2021Journal of cancer research and therapeutics
  150. Risk factors for lymph node metastasis and surgical scope in patients with cN0 non-small cell lung cancer: a single-center study in China.2021Journal of cardiothoracic surgery免费全文
  151. Engineering of gemcitabine coated nano-graphene oxide sheets for efficient near-infrared radiation mediated in vivo lung cancer photothermal therapy.2021Journal of photochemistry and photobiology. B, Biology
  152. UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma.2021Journal of translational medicine免费全文
  153. Development of metastasis-associated seven gene signature for predicting lung adenocarcinoma prognosis using single-cell RNA sequencing data.2021Mathematical biosciences and engineering : MBE
  154. FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect.2021Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  155. CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway.2021Pulmonary pharmacology & therapeutics
  156. High prognostic nutritional index (PNI) as a positive prognostic indicator for non-small cell lung cancer patients with bone metastasis.2021The clinical respiratory journal
中文论文(未计入)3
  1. [Research Progress on the Protective Effect of Intestinal Flora on 
Radiation-induced Lung Injury in Thoracic Tumors].2023Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  2. [Progress of Immune Checkpoint Inhibitors 
in the Treatment of Advanced Pulmonary Neuroendocrine Tumors].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  3. [Research Progress of Immune Checkpoint Inhibitors 
in Malignant Pleural Mesothelioma].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)161
  1. Study of DC-CTL Combined With CIK for Advanced Solid Tumor状态不明NCT03047525牵头方(推断)I/II期2017-02 启动
  2. A Study of DS-3939a in Participants With Solid Tumors正在招募NCT07739966研究中心I/II期2026-10 启动
  3. A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection正在招募NCT07367529研究中心I/II期2026-02 启动
  4. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion正在招募NCT07063745研究中心II/III期2026-01 启动
  5. A Phase 2 Study of ABSK043 Combined With Osimertinib即将招募NCT07710612研究中心II期2026-08 启动
  6. A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)正在招募NCT07227597研究中心I/II期2026-01 启动
  7. A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)正在招募NCT07622186研究中心II期2026-07 启动
  8. DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy正在招募NCT07472517研究中心III期2026-04 启动
  9. A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.即将招募NCT07623642研究中心II期2026-06 启动
  10. A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)正在招募NCT07843940研究中心I/II期2026-10 启动
  11. A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer正在招募NCT07253142研究中心II期2026-02 启动
  12. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)正在招募NCT07416474研究中心III期2026-04 启动
  13. First in Human Study of SIM0610 in Solid Tumors正在招募NCT07348211研究中心I期2026-01 启动
  14. A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer即将招募NCT07550842研究中心I期2026-06 启动
  15. Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer即将招募NCT07912268研究中心I期2026-11 启动
  16. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations正在招募NCT07195695研究中心III期2026-01 启动
  17. A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer正在招募NCT07227025研究中心I/II期2026-03 启动
  18. Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer正在招募NCT06801834研究中心III期2025-04 启动
  19. A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases正在招募NCT07143045研究中心2025-12 启动
  20. A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC正在招募NCT06962865研究中心II期2025-06 启动
  21. Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.即将招募NCT06885840研究中心II期2025-03 启动
  22. Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy正在招募NCT06862869研究中心2025-04 启动
  23. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)正在招募NCT06875310研究中心III期2025-04 启动
  24. A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib正在招募NCT07164170研究中心II期2025-09 启动
  25. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.正在招募NCT06758401研究中心III期2025-07 启动
  26. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations正在招募NCT07185997研究中心III期2025-12 启动
  27. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery正在招募NCT07182682研究中心III期2025-12 启动
  28. Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer正在招募NCT06712355研究中心III期2025-02 启动
  29. A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors正在招募NCT07169994研究中心I/II期2025-09 启动
  30. A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies正在招募NCT06839105研究中心I期2025-02 启动
  31. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer正在招募NCT06793215研究中心III期2025-10 启动
  32. A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)正在招募NCT07218146研究中心III期2025-11 启动
  33. A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)正在招募NCT07144280研究中心III期2025-09 启动
  34. Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer正在招募NCT06899126研究中心III期2025-10 启动
  35. A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy正在招募NCT07010263研究中心III期2025-06 启动
  36. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer正在招募NCT06890598研究中心III期2025-03 启动
  37. A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer正在招募NCT07217301研究中心III期2025-11 启动
  38. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)正在招募NCT06568939研究中心II期2025-01 启动
  39. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%正在招募NCT06561386研究中心III期2024-10 启动
  40. A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)正在招募NCT06452277研究中心III期2024-08 启动
  41. A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality正在招募NCT06496490研究中心II期2024-08 启动
  42. A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer正在招募NCT06203210研究中心III期2024-05 启动
  43. A Phase 2 Clinical Study of ABSK061 and ABSK043正在招募NCT06632262研究中心II期2024-11 启动
  44. A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib正在招募NCT06668103研究中心II期2024-11 启动
  45. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)正在招募NCT06345729研究中心III期2024-05 启动
  46. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  47. Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor正在招募NCT07433283研究中心I/II期2024-11 启动
  48. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]正在招募NCT06422143研究中心III期2024-06 启动
  49. A Study of ZL-1310 in Subjects With Small Cell Lung Cancer正在招募NCT06179069研究中心I期2024-01 启动
  50. A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors正在招募NCT06403735研究中心I期2024-04 启动
  51. JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation正在招募NCT06416410研究中心III期2024-08 启动
  52. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer正在招募NCT06119581研究中心III期2023-12 启动
  53. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)正在招募NCT05920356研究中心III期2023-11 启动
  54. A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer即将招募NCT05990127研究中心III期2023-11 启动
  55. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC正在招募NCT06010329研究中心II期2023-12 启动
  56. A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation正在招募NCT05789082研究中心I/II期2023-06 启动
  57. Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)正在招募NCT06095583研究中心III期2023-11 启动
  58. YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations即将招募NCT05767892研究中心III期2023-05 启动
  59. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)正在招募NCT06170788研究中心III期2023-12 启动
  60. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)正在招募NCT04928846研究中心III期2022-03 启动
  61. Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation正在招募NCT05288205研究中心I/II期2022-04 启动
  62. A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer正在招募NCT05498428研究中心II期2022-11 启动
  63. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer正在招募NCT05168566研究中心II期2022-09 启动
  64. A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors正在招募NCT04913285研究中心I期2021-08 启动
  65. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors正在招募NCT04930432研究中心I/II期2021-09 启动
  66. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)正在招募NCT04886804研究中心I期2021-07 启动
  67. First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)正在招募NCT05099172研究中心I/II期2021-10 启动
  68. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors正在招募NCT05024214研究中心I/II期2021-11 启动
  69. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7正在招募NCT04613596研究中心II/III期2020-12 启动
  70. Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer正在招募NCT04270591研究中心I/II期2019-07 启动
  71. A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC进行中,不再招募NCT06883630研究中心I期2025-03 启动
  72. Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy已终止NCT06924606研究中心II期2025-07 启动
  73. A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)进行中,不再招募NCT07005128研究中心III期2025-08 启动
  74. A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer进行中,不再招募NCT07005336研究中心II期2025-01 启动
  75. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)进行中,不再招募NCT06710132研究中心I/II期2025-01 启动
  76. Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib进行中,不再招募NCT06120140研究中心II期2024-02 启动
  77. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors进行中,不再招募NCT06586515研究中心I期2024-09 启动
  78. A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients状态不明NCT06469879研究中心III期2024-09 启动
  79. ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer已完成NCT06498479研究中心III期2024-07 启动
  80. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors进行中,不再招募NCT06257264研究中心I期2024-03 启动
  81. A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer进行中,不再招募NCT06711900研究中心III期2024-10 启动
  82. Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)进行中,不再招募NCT06305754研究中心III期2024-06 启动
  83. Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment进行中,不再招募NCT06502977研究中心II期2024-08 启动
  84. A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer进行中,不再招募NCT06225804研究中心I期2024-02 启动
  85. A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer进行中,不再招募NCT06448312研究中心III期2024-06 启动
  86. A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations进行中,不再招募NCT06644768研究中心I/II期2024-10 启动
  87. Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment进行中,不再招募NCT06151574研究中心III期2024-02 启动
  88. A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer进行中,不再招募NCT06984588研究中心II/III期2024-03 启动
  89. PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer进行中,不再招募NCT06616532研究中心III期2024-11 启动
  90. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients进行中,不再招募NCT05899608研究中心III期2023-10 启动
  91. A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery已完成NCT05872763研究中心2023-08 启动
  92. A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer已完成NCT05635708研究中心II期2023-02 启动
  93. Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)进行中,不再招募NCT05555732研究中心III期2023-01 启动
  94. A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)进行中,不再招募NCT05816252研究中心II期2023-04 启动
  95. A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer已完成NCT06029127研究中心II期2023-10 启动
  96. A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC进行中,不再招募NCT05844150研究中心II期2023-06 启动
  97. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)进行中,不再招募NCT06074588研究中心III期2023-11 启动
  98. Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)进行中,不再招募NCT05609968研究中心III期2023-02 启动
  99. H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC状态不明NCT05552781研究中心I/II期2022-08 启动
  100. Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)已终止NCT05226598研究中心III期2022-03 启动
  101. Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations进行中,不再招募NCT05215340研究中心III期2022-03 启动
  102. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)进行中,不再招募NCT05668988研究中心III期2022-12 启动
  103. A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer进行中,不再招募NCT05297890研究中心II期2022-05 启动
  104. A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC进行中,不再招募NCT05879068研究中心II期2022-05 启动
  105. A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer进行中,不再招募NCT05353257研究中心III期2022-05 启动
  106. Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)进行中,不再招募NCT05224141研究中心III期2022-03 启动
  107. A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer进行中,不再招募NCT05388669研究中心III期2022-08 启动
  108. Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer进行中,不再招募NCT05195632研究中心II期2022-06 启动
  109. Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer状态不明NCT05416775研究中心I/II期2022-08 启动
  110. AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer已终止NCT04993391研究中心I/II期2021-07 启动
  111. Bintrafusp Alfa Program Rollover Study已完成NCT05061823研究中心III期2021-12 启动
  112. A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases进行中,不再招募NCT04603807研究中心III期2021-09 启动
  113. A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure进行中,不再招募NCT04988295研究中心III期2021-11 启动
  114. Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer已终止NCT04921358研究中心III期2021-07 启动
  115. A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer已终止NCT04746924研究中心III期2021-05 启动
  116. Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)进行中,不再招募NCT05712902研究中心II期2021-07 启动
  117. Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer已完成NCT05014815研究中心II期2021-11 启动
  118. A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer已终止NCT04308785研究中心II期2021-12 启动
  119. A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)进行中,不再招募NCT04819100研究中心III期2021-12 启动
  120. Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)已终止NCT04738487研究中心III期2021-04 启动
  121. Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)进行中,不再招募NCT04656652研究中心III期2020-12 启动
  122. A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer已完成NCT04426825研究中心II期2020-09 启动
  123. Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer已完成NCT04665856研究中心III期2020-12 启动
  124. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  125. A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer状态不明NCT04398940研究中心II期2020-08 启动
  126. Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy已完成NCT04447118研究中心III期2020-09 启动
  127. Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer已完成NCT04205812研究中心III期2020-09 启动
  128. HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer状态不明NCT04750083研究中心II/III期2020-09 启动
  129. A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)状态不明NCT04234607研究中心III期2020-01 启动
  130. A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer进行中,不再招募NCT04194944研究中心III期2020-02 启动
  131. A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer已完成NCT04294810研究中心III期2020-03 启动
  132. A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)已完成NCT04194203研究中心III期2020-04 启动
  133. A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions进行中,不再招募NCT04538664研究中心III期2020-10 启动
  134. Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)进行中,不再招募NCT04379635研究中心III期2020-05 启动
  135. A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer进行中,不再招募NCT04487080研究中心III期2020-09 启动
  136. Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer已完成NCT04005716研究中心III期2019-07 启动
  137. Cancer Genome Atlas of China:Lung Cancer状态不明NCT04266483研究中心2019-11 启动
  138. A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer状态不明NCT04439890研究中心III期2019-08 启动
  139. A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China已完成NCT03909971研究中心II期2019-04 启动
  140. Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer(NSCLC)已完成NCT03693547研究中心II期2019-04 启动
  141. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer状态不明NCT04641754研究中心II期2019-03 启动
  142. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)进行中,不再招募NCT03974022研究中心I/II期2019-07 启动
  143. A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC状态不明NCT03668496研究中心III期2018-11 启动
  144. A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer已完成NCT03594747研究中心III期2018-07 启动
  145. A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer已终止NCT03516084研究中心III期2018-08 启动
  146. A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer已完成NCT03663205研究中心III期2018-07 启动
  147. Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer进行中,不再招募NCT03539536研究中心II期2018-10 启动
  148. A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)已终止NCT03033511研究中心III期2017-02 启动
  149. Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)已完成NCT03358875研究中心III期2017-11 启动
  150. A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy已完成NCT02813785研究中心III期2016-07 启动
  151. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients状态不明NCT04237805研究中心I/II期2016-11 启动
  152. A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)已完成NCT02763579研究中心III期2016-06 启动
  153. A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)已完成NCT02838420研究中心III期2016-08 启动
  154. Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)已完成NCT02568267研究中心II期2015-11 启动
  155. Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China已完成NCT02458651研究中心2015-06 启动
  156. Avelumab in First-line NSCLC (JAVELIN Lung 100)已完成NCT02576574研究中心III期2015-10 启动
  157. A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer已完成NCT02031744研究中心III期2014-01 启动
  158. Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer状态不明NCT02215356研究中心II期2014-08 启动
  159. A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy已完成NCT01364012研究中心III期2011-05 启动
  160. Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations状态不明NCT01410214研究中心II期2011-05 启动
  161. Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis已终止NCT00492843研究中心IV期2007-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 27 篇,占 0.5%。

牵头论文
27
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
14
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 4420222023: 8820232024: 5520242025: 552025

哈尔滨有 3 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

这家医院参与的开放试验 14

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
    分期
    I/II期
    开始
    2026-07
    发布
    登记号
    NCT07640295

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、哈尔滨、太原、杭州、武汉、郑州、长沙

  2. 正在招募
    Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
    分期
    I/II期
    开始
    2025-04
    发布
    登记号
    NCT06821503

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、南昌、哈尔滨、天津、沈阳、西安、郑州

  3. 正在招募
    A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
    分期
    III期
    开始
    2025-06
    发布
    登记号
    NCT06953999

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、哈尔滨、杭州

  4. 正在招募
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    分期
    I期
    开始
    2025-07
    发布
    登记号
    NCT07066657

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、北京、哈尔滨、杭州、武汉、郑州、长沙

  5. 正在招募
    Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
    分期
    III期
    开始
    2025-07
    发布
    登记号
    NCT07823049

    年龄未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、太原、常州、广州、成都、扬州、杭州、武汉、沈阳、福州、西安、郑州、重庆、银川、长春、长沙

  6. 正在招募
    A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
    分期
    II/III期
    开始
    2024-05
    发布
    登记号
    NCT06361888

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、合肥、哈尔滨、天津、广州、成都、昆明、杭州、武汉、沈阳、济南、海口、深圳、温州、福州、苏州、西安、郑州、重庆、长沙

  7. 正在招募
    A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
    分期
    I期
    开始
    2024-04
    发布
    登记号
    NCT06403735

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、南昌、哈尔滨、昆明

  8. 正在招募
    Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
    分期
    I/II期
    开始
    2024-11
    发布
    登记号
    NCT07433283

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、成都、海口、福州、郑州、重庆、长沙

  9. 正在招募
    A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
    分期
    II期
    开始
    2023-10
    发布
    登记号
    NCT06008288

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、济南、福州、西安、郑州、长沙、青岛

  10. 正在招募
    A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
    分期
    II期
    开始
    2023-10
    发布
    登记号
    NCT06111274

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、哈尔滨、成都、武汉

  11. 正在招募
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
    分期
    I/II期
    开始
    2022-04
    发布
    登记号
    NCT05288205

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、北京、厦门、合肥、哈尔滨、广州、武汉、沈阳、济南、深圳、福州、郑州、长沙

  12. 正在招募
    Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
    分期
    III期
    开始
    2022-12
    发布
    登记号
    NCT05653453

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、哈尔滨

  13. 正在招募
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    分期
    I期
    开始
    2021-06
    发布
    登记号
    NCT04900818

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、郑州

  14. 即将招募
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    分期
    II期
    开始
    2026-06
    发布
    登记号
    NCT07623642

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、哈尔滨

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科放疗科消化/肝病科普外/肝胆胰外科
牵头的论文27
  1. TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Exploring the genetic link between gastroesophageal reflux disease and pancreatic cancer: insights from Mendelian randomization.2025BMC cancer免费全文
  3. The combination of gemcitabine and albumin-bound paclitaxel effectively inhibits de novo lipogenesis in pancreatic cancer cells by targeting the AMPK/SREBP1 pathway.2025Biochemical pharmacology
  4. Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild-Type Pancreatic Cancer.2025Cancer science免费全文
  5. Engineered exosomes: a promising approach for overcoming challenges in pancreatic cancer therapy.2025Journal of nanobiotechnology免费全文
  6. Age-period-cohort analysis of global, regional, and national pancreatic cancer incidence, mortality, and disability-adjusted life years, 1990-2019.2024BMC cancer免费全文
  7. Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy.2024Cancer medicine免费全文
  8. VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated macrophage.2024Cell communication and signaling : CCS免费全文
  9. BNIP3+ fibroblasts associated with hypoxia and inflammation predict prognosis and immunotherapy response in pancreatic ductal adenocarcinoma.2024Journal of translational medicine免费全文
  10. Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma.2024The oncologist免费全文
  11. Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma.2023BMC cancer免费全文
  12. Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer.2023BMC cancerRCT免费全文
  13. Prediction scores of postoperative liver metastasis and long-term survival of pancreatic head cancer based on the distance between the mesenteric vessels and tumor, preoperative serum carbohydrate antigen 19-9 level, and lymph node metastas2023Cancer medicine免费全文
  14. Splicing transcriptome-wide association study to identify splicing events for pancreatic cancer risk.2023Carcinogenesis
  15. HNF4G stimulates the development of pancreatic cancer by promoting IGF2BP2 transcription.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  16. Inhibition of autophagy promotes sonodynamic therapy-induced apoptosis of pancreatic cancer cells.2023Folia histochemica et cytobiologica
  17. Extracellular vesicle-derived LINC00511 promotes glycolysis and mitochondrial oxidative phosphorylation of pancreatic cancer through macrophage polarization by microRNA-193a-3p-dependent regulation of plasminogen activator urokinase.2023Immunopharmacology and immunotoxicology
  18. Prognostic value of albumin-bilirubin score in pancreatic cancer patients after pancreatoduodenectomy with liver metastasis following radiofrequency ablation.2023Pathology oncology research : POR免费全文
  19. The outcome of intravenous and inhalation anesthesia after pancreatic cancer resection: a retrospective study.2022BMC anesthesiology免费全文
  20. HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis.2022Cancer letters
  21. Classification and Prognosis Analysis of Pancreatic Cancer Based on DNA Methylation Profile and Clinical Information.2022Genes免费全文
  22. GPR120 promotes metastasis but inhibits tumor growth in pancreatic ductal adenocarcinoma.2022Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  23. Determination of Deformable Image Registration Algorithms for Accumulating Dose in Carbon-ion Radiotherapy for Pancreatic Cancer.2021Anticancer research
  24. Silencing of FTX suppresses pancreatic cancer cell proliferation and invasion by upregulating miR-513b-5p.2021BMC cancer免费全文
  25. The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study.2021Cancer medicine免费全文
  26. Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer.2021Cancer research and treatment免费全文
  27. Adaptive planning based on single beam optimization in passive scattering carbon ion radiotherapy for patients with pancreatic cancer.2021Radiation oncology (London, England)免费全文
中文论文(未计入)1
  1. [The impact of the dosage of intraoperative opioids on postoperative survival outcomes in patients with pancreatic cancer].2022Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)25
  1. A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.即将招募NCT07623642研究中心II期2026-06 启动
  2. Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations正在招募NCT07640295研究中心I/II期2026-07 启动
  3. Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C正在招募NCT06821503研究中心I/II期2025-04 启动
  4. Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy正在招募NCT07823049研究中心III期2025-07 启动
  5. A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer正在招募NCT06953999研究中心III期2025-06 启动
  6. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors正在招募NCT07066657研究中心I期2025-07 启动
  7. A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer正在招募NCT06361888研究中心II/III期2024-05 启动
  8. Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor正在招募NCT07433283研究中心I/II期2024-11 启动
  9. A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors正在招募NCT06403735研究中心I期2024-04 启动
  10. A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.正在招募NCT06008288研究中心II期2023-10 启动
  11. A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer正在招募NCT06111274研究中心II期2023-10 启动
  12. Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer正在招募NCT05653453研究中心III期2022-12 启动
  13. Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation正在招募NCT05288205研究中心I/II期2022-04 启动
  14. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors正在招募NCT04900818研究中心I期2021-06 启动
  15. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)进行中,不再招募NCT06710132研究中心I/II期2025-01 启动
  16. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors进行中,不再招募NCT06586515研究中心I期2024-09 启动
  17. A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)进行中,不再招募NCT06360354研究中心I期2024-05 启动
  18. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  19. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors已完成NCT04400383研究中心I期2020-06 启动
  20. A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer状态不明NCT03721744研究中心II/III期2018-10 启动
  21. Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)已完成NCT03377491研究中心III期2018-05 启动
  22. A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma已完成NCT02993731研究中心III期2016-12 启动
  23. Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)已完成NCT02568267研究中心II期2015-11 启动
  24. A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer已完成NCT02395016研究中心III期2015-04 启动
  25. Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer状态不明NCT02278458研究中心I期2014-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 168 篇,占 1.0%。

牵头论文
168
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
38
由其他机构牵头
每年牵头的论文数
2021: 252520212022: 303020222023: 292920232024: 424220242025: 37372025

哈尔滨有 4 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 39

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
    分期
    II期
    开始
    2026-07
    发布
    登记号
    NCT07752550

    年龄 18 岁 至 100 岁;仅女性(登记的条件)

    牵头:哈尔滨医科大学附属肿瘤医院哈尔滨

  2. 正在招募
    A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
    分期
    I/II期
    开始
    2026-01
    发布
    登记号
    NCT07281976

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心南京、哈尔滨、广州、沈阳、郑州、长春

  3. 正在招募
    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
    分期
    未注明
    开始
    2026-01
    发布
    登记号
    NCT07347600

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、扬州、武汉、沈阳、济南、海口、潍坊、石家庄、西安、贵阳、郑州、重庆、长春

  4. 正在招募
    Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
    分期
    II期
    开始
    2026-02
    发布
    登记号
    NCT07383818

    年龄 18 岁 至 70 岁;仅女性(登记的条件)

    牵头:浙江大学医学院附属第一医院;另有 4 家列出的医院为研究中心上海、合肥、哈尔滨、杭州、西安

  5. 正在招募
    BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
    分期
    III期
    开始
    2026-05
    发布
    登记号
    NCT07492641

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、哈尔滨、天津、广州、成都、昆明、杭州、武汉、汕头、海口、温州、潍坊、石家庄、福州、蚌埠、西安、郑州、重庆、长沙

  6. 正在招募
    A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
    分期
    II期
    开始
    2026-10
    发布
    登记号
    NCT07876557

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心兰州、北京、南京、南昌、哈尔滨、太原、广州、成都、武汉、沈阳、济南、潍坊、石家庄、福州、贵阳、郑州、银川、长春、长沙、青岛

  7. 正在招募
    A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
    分期
    I/II期
    开始
    2025-01
    发布
    登记号
    NCT06679036

    年龄 18 岁 至 75 岁;仅女性(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心哈尔滨、郑州

  8. 正在招募
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    分期
    III期
    开始
    2025-04
    发布
    登记号
    NCT06790693

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心乌鲁木齐、北京、南宁、哈尔滨、天津、广州、成都、昆明、杭州、济南、襄阳、西安、长沙

  9. 正在招募
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    分期
    II/III期
    开始
    2025-06
    发布
    登记号
    NCT06891833

    年龄 18 岁 至 75 岁;仅女性(登记的条件)

    牵头方不是列出的医院;另有 26 家列出的医院为研究中心上海、南宁、南昌、合肥、哈尔滨、天津、太原、安阳、广州、成都、杭州、洛阳、济南、海口、深圳、石家庄、福州、蚌埠、西安、郑州、重庆、长沙

  10. 正在招募
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    分期
    III期
    开始
    2025-06
    发布
    登记号
    NCT06966700

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 21 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、厦门、合肥、哈尔滨、杭州、武汉、济南、西安、郑州、长春、长沙

  11. 正在招募
    Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
    分期
    III期
    开始
    2025-03
    发布
    登记号
    NCT06977893

    年龄 18 岁 至 75 岁;仅女性(登记的条件)

    牵头:浙江大学医学院附属第一医院;另有 9 家列出的医院为研究中心上海、乌鲁木齐、南昌、合肥、哈尔滨、杭州、西安、郑州

  12. 正在招募
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    分期
    III期
    开始
    2025-09
    发布
    登记号
    NCT07043725

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 52 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、台州、合肥、哈尔滨、天津、太原、宁波、安阳、广州、成都、新乡、梅州、武汉、汕头、沈阳、泉州、泸州、洛阳、济南、温州、潍坊、烟台、石家庄、蚌埠、衡阳、西安、贵阳、郑州、重庆、长春、长沙

  13. 正在招募
    JS207 Combination Therapy in Triple-negative Breast Cancer
    分期
    II期
    开始
    2025-09
    发布
    登记号
    NCT07045311

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心乌鲁木齐、北京、南京、合肥、哈尔滨、大连、杭州、武汉、沈阳、石家庄、西安、郑州、长春、青岛

  14. 正在招募
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
    分期
    III期
    开始
    2025-07
    发布
    登记号
    NCT07047365

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 44 家列出的医院为研究中心兰州、北京、南京、南充、南宁、南昌、合肥、哈尔滨、唐山、天津、太原、宁波、安阳、徐州、成都、新乡、昆明、沈阳、泸州、洛阳、济南、海口、深圳、温州、潍坊、石家庄、蚌埠、襄阳、西宁、西安、贵阳、郑州、重庆、长春、长沙

  15. 正在招募
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
    分期
    III期
    开始
    2025-08
    发布
    登记号
    NCT07062965

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、大连、广州、杭州、武汉、济南、温州、石家庄、福州、西安、长春、长沙

  16. 正在招募
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    分期
    I/II期
    开始
    2025-09
    发布
    登记号
    NCT07169994

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、南京、南昌、合肥、哈尔滨、天津、太原、安阳、广州、成都、梅州、沈阳、洛阳、福州、襄阳

  17. 正在招募
    A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07174336

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、哈尔滨、天津、安阳、广州、成都、武汉、汕头、福州、长春、长沙

  18. 正在招募
    An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
    分期
    I期
    开始
    2025-12
    发布
    登记号
    NCT07222267

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、厦门、哈尔滨、天津、杭州、重庆、长沙

  19. 正在招募
    Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
    分期
    不分期
    开始
    2025-10
    发布
    登记号
    NCT07469267

    年龄 18 岁 至 未注明;仅女性(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 12 家列出的医院为研究中心上海、哈尔滨、天津、宁波、杭州、武汉、济南、石家庄、贵阳、长沙

  20. 正在招募
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    分期
    III期
    开始
    2025-01
    发布
    登记号
    NCT07673029

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 51 家列出的医院为研究中心上海、临沂、北京、南宁、南昌、合肥、哈尔滨、大连、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、梅州、武汉、汕头、沈阳、泉州、洛阳、济南、潍坊、烟台、石家庄、福州、蚌埠、西安、贵阳、郑州、重庆、长春、长沙、青岛

  21. 正在招募
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    分期
    未注明
    开始
    2024-01
    发布
    登记号
    NCT06210776

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、乌鲁木齐、佛山、北京、南京、南昌、南通、合肥、哈尔滨、唐山、天津、太原、广州、徐州、成都、新乡、昆明、杭州、汕头、沈阳、洛阳、深圳、潍坊、珠海、福州、西安、郑州、银川、青岛

  22. 正在招募
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    分期
    I/II期
    开始
    2024-06
    发布
    登记号
    NCT06324357

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、南京、哈尔滨、天津、杭州、郑州、长春

  23. 正在招募
    The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06452706

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、乌鲁木齐、哈尔滨、杭州、武汉、西安

  24. 正在招募
    A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
    分期
    I期
    开始
    2024-08
    发布
    登记号
    NCT06503783

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、哈尔滨

  25. 正在招募
    Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
    分期
    II期
    开始
    2024-06
    发布
    登记号
    NCT06611813

    年龄 18 岁 至 75 岁;仅女性(登记的条件)

    牵头:浙江大学医学院附属第一医院;另有 6 家列出的医院为研究中心上海、乌鲁木齐、合肥、哈尔滨、杭州、郑州

  26. 正在招募
    Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
    分期
    II期
    开始
    2024-10
    发布
    登记号
    NCT06682195

    年龄 18 岁 至 70 岁;仅女性(登记的条件)

    牵头:浙江大学医学院附属第一医院;另有 10 家列出的医院为研究中心上海、乌鲁木齐、南昌、合肥、哈尔滨、太原、杭州、西安、郑州

  27. 正在招募
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
    分期
    II/III期
    开始
    2023-09
    发布
    登记号
    NCT05860465

    年龄 18 岁 至 75 岁;仅女性(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心北京、南京、哈尔滨、天津、安阳、广州、昆明、杭州、沈阳、洛阳、石家庄、福州、蚌埠、西安、银川、长春

  28. 正在招募
    Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
    分期
    II期
    开始
    2023-09
    发布
    登记号
    NCT05872347

    年龄 18 岁 至 75 岁;仅女性(登记的条件)

    牵头方不是列出的医院;另有 21 家列出的医院为研究中心乌鲁木齐、北京、南京、南宁、合肥、哈尔滨、天津、安阳、广州、杭州、武汉、洛阳、石家庄、蚌埠、襄阳、郑州、银川、长春

  29. 正在招募
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    分期
    III期
    开始
    2023-12
    发布
    登记号
    NCT06079983

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 60 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、大连、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、梅州、武汉、汕头、沈阳、洛阳、济南、湛江、石家庄、福州、苏州、衡阳、襄阳、西宁、西安、贵阳、遵义、郑州、重庆、长春、长沙、青岛

  30. 正在招募
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    分期
    II期
    开始
    2023-12
    发布
    登记号
    NCT06107686

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南宁、南昌、台州、合肥、哈尔滨、太原、广州、徐州、成都、杭州、桂林、梅州、武汉、汕头、沈阳、济南、潍坊、苏州、襄阳、西安、郑州、重庆、长春、长沙、青岛

  31. 正在招募
    BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
    分期
    I期
    开始
    2023-12
    发布
    登记号
    NCT06120283

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、北京、南昌、哈尔滨、广州、沈阳、福州

  32. 正在招募
    A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
    分期
    III期
    开始
    2022-09
    发布
    登记号
    NCT06954961

    年龄 18 岁 至 75 岁;仅女性(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、哈尔滨

  33. 正在招募
    Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
    分期
    IV期
    开始
    2021-07
    发布
    登记号
    NCT04136782

    年龄 18 岁 至 70 岁;仅女性(登记的条件)

    牵头:中国医科大学附属盛京医院;另有 3 家列出的医院为研究中心哈尔滨、沈阳、长春

  34. 正在招募
    Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
    分期
    未注明
    开始
    2021-07
    发布
    登记号
    NCT04476485

    年龄 18 岁 至 70 岁;仅女性(登记的条件)

    牵头:中国医科大学附属盛京医院;另有 3 家列出的医院为研究中心哈尔滨、沈阳、长春

  35. 即将招募
    Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
    分期
    II期
    开始
    2026-04
    发布
    登记号
    NCT07487519

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心哈尔滨

  36. 即将招募
    A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
    分期
    I/II期
    开始
    2026-06
    发布
    登记号
    NCT07560124

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、哈尔滨、成都

  37. 即将招募
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    分期
    II期
    开始
    2026-06
    发布
    登记号
    NCT07623642

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、哈尔滨

  38. 即将招募
    A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
    分期
    II期
    开始
    2024-04
    发布
    登记号
    NCT06354114

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心哈尔滨

  39. 邀请入组
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    分期
    II期
    开始
    2025-08
    发布
    登记号
    NCT07376629

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、临沂、南京、厦门、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、杭州、武汉、沈阳、济南、福州、苏州、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科影像/核医学科放疗科病理/检验科
牵头的论文168
  1. Integrating Deep Feature Extraction and MRI Radiomics for Survival Prediction in Breast Cancer After Neoadjuvant Chemotherapy.2026Academic radiology
  2. Proteogenomic Characterization Reveals Subtype-Specific Therapeutic Potential for HER2-Low Breast Cancer.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Biomimetic Organic Nanozyme as Tumor Vaccines for Targeted Suppression of Ammonia-Induced T Lymphocyte Death to Augment Breast Cancer Immunotherapy.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  4. Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer.2026British journal of cancer免费全文
  5. TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trial.2026ESMO openRCT免费全文
  6. Novel MRI-based Hyper-Fused Radiomics for Predicting Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer.2025Academic radiology
  7. Biomimetic Single-Atom Nanozyme for Dual Starvation-Enhanced Breast Cancer Immunotherapy.2025Advanced healthcare materials
  8. Camouflaged Nanozymes with Oxidation-Promoting Activities Triggering Ferroptosis for Radio-Immunotherapy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  9. Machine learning and SHAP value interpretation for predicting the response to neoadjuvant chemotherapy and long-term clinical outcomes in Chinese female breast cancer.2025Annals of medicine免费全文
  10. Lactate dehydrogenase a is a crucial biomarker that affects the prognosis, chemotherapy effect, and immune infiltration of breast cancer.2025BMC women's health免费全文
  11. Novel models based on machine learning to predict the prognosis of metaplastic breast cancer.2025Breast (Edinburgh, Scotland)免费全文
  12. Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.2025Cancer communications (London, England)免费全文
  13. Development and validation of nomograms to predict brain metastasis-free survival in lung and breast cancer.2025Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  14. An Approach for Differential Diagnosis of Breast Tumors by ctDNA Methylation Sequencing.2025Cancer medicine免费全文
  15. Lnc-TPT1-AS1/CBP/ATIC Axis Mediated Purine Metabolism Activation Promotes Breast Cancer Progression.2025Cancer science免费全文
  16. LHPP-P38 MAPK/ERK-ETS1 Axis Negative Feedback Signaling Restrains Progression in Breast Cancer.2025Cancer science免费全文
  17. ZMIZ1 lactylation induces tamoxifen resistance in breast cancer through increasing transcriptional activity of Nanog to impact cell stemness and cholesterol uptake.2025Cell biology and toxicology免费全文
  18. In Triple-Negative Breast Cancer: Correlation Among Metabolic Syndrome, S100A7/cPLA2 Expression and the Efficacy of Neoadjuvant Chemotherapy.2025Clinical breast cancer
  19. The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  20. Tumor vascular normalization by B7-H3 blockade augments T lymphocyte-mediated antitumor immunity.2025European journal of pharmacology
  21. Pan-immune-inflammation value predicts survival in inflammatory breast cancer patients.2025Experimental biology and medicine (Maywood, N.J.)免费全文
  22. Association of the inflammatory microenvironment of obesity with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.2025Frontiers in endocrinology免费全文
  23. Necrosis by sodium overload-associated genes TRPM4 and SLC9A1: biological roles and clinical implications in breast cancer progression.2025Frontiers in immunology免费全文
  24. Integrating deep learning features from mammography with SHAP values for a machine learning model predicting over 5-year recurrence of breast ductal carcinoma In Situ post-lumpectomy.2025Frontiers in immunology免费全文
  25. Association of microtubule-based processes gene expression with immune microenvironment and its predictive value for drug response in oestrogen receptor-positive breast cancer.2025Frontiers in immunology免费全文
  26. Current state of cancer immunity cycle: new strategies and challenges of using precision hydrogels to treat breast cancer.2025Frontiers in immunology免费全文
  27. Fundamental knowledge and research regarding the role of immunity in triple-negative breast cancer from 2014-2024: A bibliometric analysis.2025Human vaccines & immunotherapeutics免费全文
  28. SMC4 promotes immune evasion by inhibiting endogenous interferon signaling and upregulating PD-L1 expression in triple negative breast cancer.2025International immunopharmacology
  29. Exosomal miR-3529-3p increases the sensitivity of trastuzumab via Wnt/β-catenin signaling pathway by targeting HOOK3.2025International immunopharmacology
  30. PSMD14 promotes breast cancer progression by reducing K63-linked ubiquitination on FOXM1 and activating the PI3K/AKT/mTOR pathway.2025International journal of biological macromolecules
  31. HSP90 inhibitor-loaded hollow mesoporous nanoparticles for enhanced synergistic mild photothermal/chemotherapy in triple negative breast cancer.2025International journal of biological macromolecules
  32. Molecular characterization of breast cancer and multiple primary malignancies: the latest application using unmarked quantitative proteomics.2025International journal of surgery (London, England)免费全文
  33. FTO activates PD-L1 promotes immunosuppression in breast cancer via the m6A/YTHDF3/PDK1 axis under hypoxic conditions.2025Journal of advanced research免费全文
  34. H4K79 and H4K91 histone lactylation, newly identified lactylation sites enriched in breast cancer.2025Journal of experimental & clinical cancer research : CR免费全文
  35. Machine learning-based identification of kbhb-affected tumor cell subsets as prognostic and therapeutic targets in breast cancer.2025Journal of translational medicine免费全文
  36. Application of mass cytometry in the immune microenvironment of breast cancer.2025Medical oncology (Northwood, London, England)
  37. Comprehensive analysis of the biological functions and prognostic significance of GDI1 in breast cancer.2025Medicine免费全文
  38. Preoperative inflammatory status as a positive prognostic factor for triple-negative breast cancer patients receiving neoadjuvant therapy.2025Medicine免费全文
  39. Transcriptome-wide analysis reveals potential roles of CFD and ANGPTL4 in fibroblasts regulating B cell lineage for extracellular matrix-driven clustering and novel avenues for immunotherapy in breast cancer.2025Molecular medicine (Cambridge, Mass.)免费全文
  40. Harnessing the inflammatory signature: a review for biomarkers in inflammatory breast cancer.2025QJM : monthly journal of the Association of Physicians
  41. Implementation of personalized multidisciplinary neuropathy management program for chemotherapy-induced peripheral neuropathy symptoms in breast cancer patients.2025The International journal of neuroscience
  42. Extratumoral Signs of Malignant Nonspiculate and Noncalcified Masses on Mammography: Are They Associated With Prognostic Factors in Breast Cancer?2025The breast journal免费全文
  43. Cold Exposure Therapy Sensitizes Nanodrug-Mediated Radioimmunotherapy of Breast Cancer.2024ACS nano
  44. Can we skip invasive biopsy of sentinel lymph nodes? A preliminary investigation to predict sentinel lymph node status using PET/CT-based radiomics.2024BMC cancer免费全文
  45. Preoperative platelet distribution width predicts bone metastasis in patients with breast cancer.2024BMC cancer免费全文
  46. Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy.2024BMC cancer免费全文
  47. Investigation of correlation between shear wave elastography and lymphangiogenesis in invasive breast cancer and diagnosis of axillary lymph node metastasis.2024BMC cancer免费全文
  48. Diagnostic value of applying preoperative breast ultrasound and clinicopathologic features to predict axillary lymph node burden in early invasive breast cancer: a study of 1247 patients.2024BMC cancer免费全文
  49. Development of predictive models for pathological response status in breast cancer after neoadjuvant therapy based on peripheral blood inflammatory indexes.2024BMC women's health免费全文
  50. An antihypertensive drug-AT1 inhibitor attenuated BRCA development promoted by chronic psychological stress via Ang II/PARP1/FN1 pathway.2024Biochimica et biophysica acta. Molecular basis of disease
  51. Nanobubble-mediated co-delivery of siTRIM37 and IR780 for gene and sonodynamic combination therapy against triple negative breast cancer.2024Biomedical materials (Bristol, England)
  52. PSAT1 Promotes Metastasis via p-AKT/SP1/ITGA2 Axis in Estrogen Receptor-Negative Breast Cancer Cell.2024Biomolecules免费全文
  53. Subcutaneous fat predicts bone metastasis in breast cancer: A novel multimodality-based deep learning model.2024Cancer biomarkers : section A of Disease markers免费全文
  54. Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients.2024Cancer chemotherapy and pharmacology
  55. Identification of Novel Anoikis-Related Gene Signatures to Predict the Prognosis, Immune Microenvironment, and Drug Sensitivity of Breast Cancer Patients.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  56. The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients.2024Cancer medicine免费全文
  57. Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes.2024Cancer research and treatment免费全文
  58. A comprehensive overview of metaplastic breast cancer: Features and treatments.2024Cancer science免费全文
  59. Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells.2024Cell biology international
  60. Tumor suppressor KEAP1 promotes HSPA9 degradation, controlling mitochondrial biogenesis in breast cancer.2024Cell reports
  61. Calcium-sensing receptor and NF-κB pathways in TN breast cancer contribute to cancer-induced cardiomyocyte damage via activating neutrophil extracellular traps formation.2024Cellular and molecular life sciences : CMLS免费全文
  62. The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  63. Combination of DCE-MRI and NME-DWI via Deep Neural Network for Predicting Breast Cancer Molecular Subtypes.2024Clinical breast cancer
  64. CyTOF analysis revealed platelet heterogeneity in breast cancer patients received T-DM1 treatment.2024Clinical immunology (Orlando, Fla.)
  65. MRI-based vector radiomics for predicting breast cancer HER2 status and its changes after neoadjuvant therapy.2024Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
  66. Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer.2024Computers in biology and medicine
  67. Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy.2024Diagnostic pathology免费全文
  68. Integration of transcriptomics and machine learning for insights into breast cancer: exploring lipid metabolism and immune interactions.2024Frontiers in immunology免费全文
  69. Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer.2024International immunopharmacology
  70. The Gustave Roussy Immune score (GRIm score) as a novel prognostic score for early breast cancer patients: A real-world retrospective study.2024International journal of medical sciences免费全文
  71. RNA-Seq Reveals the Mechanism of Pyroptosis Induced by Oxygen-Enriched IR780 Nanobubbles-Mediated Sono-Photodynamic Therapy.2024International journal of nanomedicine免费全文
  72. TME-Responsive Nanoplatform with Glutathione Depletion for Enhanced Tumor-Specific Mild Photothermal/Gene/Ferroptosis Synergistic Therapy.2024International journal of nanomedicine免费全文
  73. Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II-III triple negative breast cancer: a retrospective analysis.2024Journal of cancer research and clinical oncology免费全文
  74. Recent advances in caspase-3, breast cancer, and traditional Chinese medicine: a review.2024Journal of chemotherapy (Florence, Italy)
  75. NAT10/ac4C/JunB facilitates TNBC malignant progression and immunosuppression by driving glycolysis addiction.2024Journal of experimental & clinical cancer research : CR免费全文
  76. Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells.2024Journal of leukocyte biology
  77. A Channel-Dimensional Feature-Reconstructed Deep Learning Model for Predicting Breast Cancer Molecular Subtypes on Overall b-Value Diffusion-Weighted MRI.2024Journal of magnetic resonance imaging : JMRI
  78. Responds to the Comments on "A Channel-Dimensional Feature-Reconstructed Deep Learning Model for Predicting Breast Cancer Molecular Subtypes on Overall b-Value Diffusion-Weighted MRI".2024Journal of magnetic resonance imaging : JMRI
  79. Transcription Impairment of TMEM208 by ZBTB14 Suppresses Breast cancer Radiotherapy Resistance.2024Journal of mammary gland biology and neoplasia免费全文
  80. The potential of lenvatinib in breast cancer therapy.2024Medical oncology (Northwood, London, England)
  81. Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.2024Molecular cancer免费全文
  82. Clinicopathological Characteristics of Breast Cancer Patients with HER-2 Low Expression Receiving Neoadjuvant Therapy.2024Oncology
  83. The immune regulation and therapeutic potential of the SMAD gene family in breast cancer.2024Scientific reports免费全文
  84. Calcium-sensing Receptor, a Potential Biomarker Revealed by Large-scale Public Databases and Experimental Verification in Metastatic Breast Cancer.2024Technology in cancer research & treatment免费全文
  85. Pectoralis muscle predicts distant metastases in breast cancer by deep learning radiomics.2023Acta radiologica (Stockholm, Sweden : 1987)
  86. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial.2023BMC cancer免费全文
  87. Automated Breast Ultrasound (ABUS)-based radiomics nomogram: an individualized tool for predicting axillary lymph node tumor burden in patients with early breast cancer.2023BMC cancer免费全文
  88. The prediction of distant metastasis risk for male breast cancer patients based on an interpretable machine learning model.2023BMC medical informatics and decision making免费全文
  89. Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  90. FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer.2023Breast cancer research and treatment
  91. Albumin-bilirubin score predicts trastuzumab resistance in HER2-positive breast cancer.2023Cancer biomarkers : section A of Disease markers免费全文
  92. Lower subcutaneous fat index predicts bone metastasis in breast cancer.2023Cancer biomarkers : section A of Disease markers免费全文
  93. Cytoplasmic YAP1-mediated ESCRT-III assembly promotes autophagic cell death and is ubiquitinated by NEDD4L in breast cancer.2023Cancer communications (London, England)免费全文
  94. Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer.2023Cancer genetics
  95. RMI2 is a novel prognostic and predictive biomarker for breast cancer.2023Cancer medicine免费全文
  96. Prediction of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer using a combination of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging.2023Cancer medicine免费全文
  97. LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1-TINCR-USP20-PD-L1 axis.2023Cell death & disease免费全文
  98. The effectiveness of ultrasound-guided core needle biopsy in detecting lymph node metastases in the axilla in patients with breast cancer: systematic review and meta-analysis.2023Clinics (Sao Paulo, Brazil)免费全文
  99. Sufentanil inhibits the metastasis and immune response of breast cancer via mediating the NF-κB pathway.2023Immunopharmacology and immunotoxicology
  100. Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab.2023Immunopharmacology and immunotoxicology
  101. Ultrasound Triggered Tumor Metabolism Suppressor Induces Tumor Starvation for Enhanced Sonodynamic Immunotherapy of Breast Cancer.2023International journal of nanomedicine免费全文
  102. Correlation analysis between androgen receptor and the clinicopathological features and prognosis of mammary Paget's disease.2023Journal of cancer research and clinical oncology免费全文
  103. Naples score: a novel prognostic biomarker for breast cancer patients undergoing neoadjuvant chemotherapy.2023Journal of cancer research and clinical oncology免费全文
  104. Clinical characteristics and pathologic complete response (pCR) rate after neoadjuvant chemotherapy in postpartum women with breast cancer.2023Journal of cancer research and clinical oncology免费全文
  105. The tremendous clinical potential of the microbiota in the treatment of breast cancer: the next frontier.2023Journal of cancer research and clinical oncology免费全文
  106. Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ.2023Journal of cancer research and clinical oncology免费全文
  107. Comparison of Dynamic Contrast-Enhanced MRI and Non-Mono-Exponential Model-Based Diffusion-Weighted Imaging for the Prediction of Prognostic Biomarkers and Molecular Subtypes of Breast Cancer Based on Radiomics.2023Journal of magnetic resonance imaging : JMRI
  108. Single-cell RNA sequencing reveals small extracellular vesicles derived from malignant cells that contribute to angiogenesis in human breast cancers.2023Journal of translational medicine免费全文
  109. Identification of Genes Associated with Prognosis and Immunotherapy Prediction in Triple-Negative Breast Cancer via M1/M2 Macrophage Ratio.2023Medicina (Kaunas, Lithuania)免费全文
  110. Targeting mitochondrial dynamics by AZD5363 in triple-negative breast cancer MDA-MB-231 cell-derived spheres.2023Naunyn-Schmiedeberg's archives of pharmacology免费全文
  111. The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo.2023Pharmacological research
  112. Early Prediction of Response to Neoadjuvant Chemotherapy Using Quantitative Parameters on Automated Breast Ultrasound Combined with Contrast-Enhanced Ultrasound in Breast Cancer.2023Ultrasound in medicine & biology
  113. Prediction of nonsentinel lymph node metastasis in breast cancer patients based on machine learning.2023World journal of surgical oncology免费全文
  114. Differences in ultrasonographic features between males and females with breast cancer of the luminal A and luminal B molecular subtypes.2022Asia-Pacific journal of clinical oncology
  115. Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy.2022BMC cancer免费全文
  116. Prediction model of axillary lymph node status using automated breast ultrasound (ABUS) and ki-67 status in early-stage breast cancer.2022BMC cancer免费全文
  117. Systematic analysis of the expression and prognostic value of ITPR1 and correlation with tumor infiltrating immune cells in breast cancer.2022BMC cancer免费全文
  118. High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.2022BMC cancer免费全文
  119. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.2022BMC medicine免费全文
  120. Deep learning radiomics under multimodality explore association between muscle/fat and metastasis and survival in breast cancer patients.2022Briefings in bioinformatics
  121. Serum amyloid A 1 induces suppressive neutrophils through the Toll-like receptor 2-mediated signaling pathway to promote progression of breast cancer.2022Cancer science免费全文
  122. Nano Carbon Tracing-based Treatment of Breast Cancer Lymphadenectomy and Nursing Intervention of Postoperative Lymphedema.2022Cellular and molecular biology (Noisy-le-Grand, France)RCT
  123. LncRNA RP11-214F16.8 drives breast cancer tumorigenesis via a post-translational repression on NISCH expression.2022Cellular signalling
  124. The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.2022Clinical breast cancer
  125. Value of shear wave elasticity in predicting the efficacy of neoadjuvant chemotherapy in different molecular types.2022Clinical imaging
  126. Investigation of the Mechanism of hsa_circ_000 1429 Adsorbed miR-205 to Regulate KDM4A and Promote Breast Cancer Metastasis.2022Contrast media & molecular imaging免费全文
  127. A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.2022Disease markers免费全文
  128. The link between aberrant splicing and B cell infiltration in breast cancer hormone therapy.2022Endocrine-related cancer
  129. Performance of novel deep learning network with the incorporation of the automatic segmentation network for diagnosis of breast cancer in automated breast ultrasound.2022European radiology
  130. Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer.2022Frontiers in immunology免费全文
  131. Computer-aided classification of MRI for pathological complete response to neoadjuvant chemotherapy in breast cancer.2022Future oncology (London, England)
  132. Revealing the Potential Markers of N(4)-Acetylcytidine through acRIP-seq in Triple-Negative Breast Cancer.2022Genes免费全文
  133. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.2022Immunopharmacology and immunotoxicology
  134. USF1-ATRAP-PBX3 Axis Promote Breast Cancer Glycolysis and Malignant Phenotype by Activating AKT/mTOR Signaling.2022International journal of biological sciences免费全文
  135. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.2022JAMA network openRCT免费全文
  136. Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling.2022Journal for immunotherapy of cancer免费全文
  137. A Novel Necroptosis-Associated lncRNA Signature Can Impact the Immune Status and Predict the Outcome of Breast Cancer.2022Journal of immunology research免费全文
  138. TPI1 activates the PI3K/AKT/mTOR signaling pathway to induce breast cancer progression by stabilizing CDCA5.2022Journal of translational medicine免费全文
  139. Long non-coding RNA ANRIL promotes chemoresistance in triple-negative breast cancer via enhancing aerobic glycolysis.2022Life sciences
  140. Characterized the diversity of ABCB1 subtypes in immunogenomic landscape for predicting the drug response in breast cancer.2022Methods (San Diego, Calif.)
  141. Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients.2022Nature communications免费全文
  142. Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression.2022Pharmacology & therapeutics
  143. Prediction of Axillary Lymph Node Metastasis in Invasive Breast Cancer by Sound Touch Elastography.2022Ultrasound in medicine & biology
  144. Expression and prognostic values of ARID family members in breast cancer.2021Aging免费全文
  145. GABARAP suppresses EMT and breast cancer progression via the AKT/mTOR signaling pathway.2021Aging免费全文
  146. The application of personalized rehabilitation exercises in the postoperative rehabilitation of breast cancer patients.2021Annals of palliative medicine
  147. Clinical Significance of Oncoplastic Breast-Conserving Surgery and Application of Volume-Displacement Technique.2021Annals of plastic surgery
  148. Highly penetrating nanobubble polymer enhances LINC00511-siRNA delivery for improving the chemosensitivity of triple-negative breast cancer.2021Anti-cancer drugs
  149. Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.2021BMC cancer免费全文
  150. Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients.2021Breast cancer research : BCR免费全文
  151. The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte.2021Cancer immunology, immunotherapy : CII免费全文
  152. HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.2021Cancer science免费全文
  153. Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization.2021Cell death & disease免费全文
  154. LncRNA TINCR favors tumorigenesis via STAT3-TINCR-EGFR-feedback loop by recruiting DNMT1 and acting as a competing endogenous RNA in human breast cancer.2021Cell death & disease免费全文
  155. Single-Cell Proteomic Profiling Identifies Nanoparticle Enhanced Therapy for Triple Negative Breast Cancer Stem Cells.2021Cells免费全文
  156. Dynamic biomarkers indicate the immunological benefits provided by Ganoderma spore powder in post-operative breast and lung cancer patients.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoRCT
  157. Nomogram Predicting the Risk of Locoregional Recurrence After Mastectomy for Invasive Micropapillary Carcinoma of the Breast.2021Clinical breast cancer
  158. NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.2021Clinical epigenetics免费全文
  159. Caspase-3-mediated GSDME induced Pyroptosis in breast cancer cells through the ROS/JNK signalling pathway.2021Journal of cellular and molecular medicine免费全文
  160. Laser-triggered combination therapy by iron sulfide-doxorubicin@functionalized nanozymes for breast cancer therapy.2021Journal of nanobiotechnology免费全文
  161. N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  162. FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect.2021Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  163. GLUT1 participates in tamoxifen resistance in breast cancer cells through autophagy regulation.2021Naunyn-Schmiedeberg's archives of pharmacology
  164. Tumor-associated macrophages increase COX-2 expression promoting endocrine resistance in breast cancer via the PI3K/Akt/mTOR pathway.2021Neoplasma
  165. Correlations of social isolation and anxiety and depression symptoms among patients with breast cancer of Heilongjiang province in China: The mediating role of social support.2021Nursing open免费全文
  166. Application of conventional ultrasonography combined with contrast-enhanced ultrasonography in the axillary lymph nodes and evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients.2021The British journal of radiology免费全文
  167. CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis.2021Theranostics免费全文
  168. AKT inhibitor AZD5363 suppresses stemness and promotes anti-cancer activity of 3,3'-diindolylmethane in human breast cancer cells.2021Toxicology and applied pharmacology
中文论文(未计入)2
  1. [Effectiveness of sequential method pure single-port lumpectomy-breast conserving surgery for early-stage breast cancer in different quadrants].2024Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery免费全文
  2. [Tyro3 and CDK9 as biomarkers for drug resistance to breast cancer anti-PD-1 therapies].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)116
  1. Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer即将招募NCT07752550牵头方(推断)II期2026-07 启动
  2. Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy进行中,不再招募NCT07471815牵头方(推断)II期2026-03 启动
  3. Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer进行中,不再招募NCT06599216牵头方(推断)II期2024-10 启动
  4. Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer状态不明NCT01483300牵头方(推断)II期2011-11 启动
  5. A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer正在招募NCT07347600研究中心2026-01 启动
  6. Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)正在招募NCT07383818研究中心II期2026-02 启动
  7. Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.即将招募NCT07487519研究中心II期2026-04 启动
  8. A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)正在招募NCT07876557研究中心II期2026-10 启动
  9. A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.即将招募NCT07623642研究中心II期2026-06 启动
  10. A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer即将招募NCT07560124研究中心I/II期2026-06 启动
  11. A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer正在招募NCT07281976研究中心I/II期2026-01 启动
  12. BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease正在招募NCT07492641研究中心III期2026-05 启动
  13. A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients正在招募NCT06679036研究中心I/II期2025-01 启动
  14. A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC邀请入组NCT07376629研究中心II期2025-08 启动
  15. A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer正在招募NCT07043725研究中心III期2025-09 启动
  16. TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer正在招募NCT07047365研究中心III期2025-07 启动
  17. Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases正在招募NCT07469267研究中心不分期2025-10 启动
  18. Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)正在招募NCT06977893研究中心III期2025-03 启动
  19. A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer正在招募NCT06891833研究中心II/III期2025-06 启动
  20. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)正在招募NCT07174336研究中心III期2025-12 启动
  21. JS207 Combination Therapy in Triple-negative Breast Cancer正在招募NCT07045311研究中心II期2025-09 启动
  22. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.正在招募NCT07062965研究中心III期2025-08 启动
  23. A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors正在招募NCT07169994研究中心I/II期2025-09 启动
  24. An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors正在招募NCT07222267研究中心I期2025-12 启动
  25. A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer正在招募NCT07673029研究中心III期2025-01 启动
  26. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer正在招募NCT06790693研究中心III期2025-04 启动
  27. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)正在招募NCT06966700研究中心III期2025-06 启动
  28. A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)正在招募NCT06210776研究中心2024-01 启动
  29. Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)正在招募NCT06682195研究中心II期2024-10 启动
  30. A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors正在招募NCT06503783研究中心I期2024-08 启动
  31. A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011即将招募NCT06354114研究中心II期2024-04 启动
  32. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread正在招募NCT06324357研究中心I/II期2024-06 启动
  33. The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer正在招募NCT06452706研究中心II期2024-11 启动
  34. Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)正在招募NCT06611813研究中心II期2024-06 启动
  35. A Study of YL202 in Selected Patients With Advanced Solid Tumors正在招募NCT06107686研究中心II期2023-12 启动
  36. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors正在招募NCT06120283研究中心I期2023-12 启动
  37. Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.正在招募NCT05872347研究中心II期2023-09 启动
  38. Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer正在招募NCT05860465研究中心II/III期2023-09 启动
  39. JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects正在招募NCT06079983研究中心III期2023-12 启动
  40. A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer正在招募NCT06954961研究中心III期2022-09 启动
  41. Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer正在招募NCT04136782研究中心IV期2021-07 启动
  42. Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy正在招募NCT04476485研究中心2021-07 启动
  43. Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer已终止NCT06851442研究中心I/II期2025-05 启动
  44. Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease进行中,不再招募NCT06760637研究中心III期2025-01 启动
  45. Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer进行中,不再招募NCT06702618研究中心II期2025-02 启动
  46. A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)进行中,不再招募NCT06680921研究中心III期2024-11 启动
  47. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors进行中,不再招募NCT06257264研究中心I期2024-03 启动
  48. PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC进行中,不再招募NCT06419621研究中心III期2024-06 启动
  49. A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer进行中,不再招募NCT06198751研究中心II期2024-02 启动
  50. A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer已完成NCT05945927研究中心2023-09 启动
  51. A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer进行中,不再招募NCT05654623研究中心III期2023-03 启动
  52. Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy进行中,不再招募NCT05840211研究中心III期2023-05 启动
  53. A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer已完成NCT06115902研究中心I期2023-11 启动
  54. A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)进行中,不再招募NCT06065748研究中心III期2023-12 启动
  55. FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer状态不明NCT05755048研究中心III期2023-03 启动
  56. A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer进行中,不再招募NCT05257395研究中心III期2022-03 启动
  57. Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC状态不明NCT05400993研究中心II期2022-05 启动
  58. Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)进行中,不再招募NCT05382364研究中心I期2022-06 启动
  59. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903已完成NCT06846099研究中心I期2022-12 启动
  60. Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies进行中,不再招募NCT05226871研究中心II期2022-07 启动
  61. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer进行中,不再招募NCT05346224研究中心III期2022-04 启动
  62. Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer进行中,不再招募NCT05382299研究中心III期2022-07 启动
  63. A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer状态不明NCT05433480研究中心III期2022-05 启动
  64. Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer进行中,不再招募NCT04851613研究中心III期2022-02 启动
  65. A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy进行中,不再招募NCT04873362研究中心III期2021-05 启动
  66. A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)进行中,不再招募NCT04961996研究中心III期2021-08 启动
  67. A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer已终止NCT04927481研究中心II期2021-06 启动
  68. A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)已终止NCT04740918研究中心III期2021-06 启动
  69. A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer已终止NCT05103826研究中心I期2021-10 启动
  70. A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer已完成NCT04796623研究中心II期2021-02 启动
  71. A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer进行中,不再招募NCT04975308研究中心III期2021-10 启动
  72. Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors状态不明NCT05145907研究中心II期2021-12 启动
  73. Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .状态不明NCT04234620研究中心2020-02 启动
  74. A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)进行中,不再招募NCT04546009研究中心III期2020-10 启动
  75. A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)进行中,不再招募NCT04622319研究中心III期2020-12 启动
  76. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  77. A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer已完成NCT04024462研究中心III期2020-02 启动
  78. A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer进行中,不再招募NCT04191499研究中心II/III期2020-01 启动
  79. A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer已完成NCT03872791研究中心I/II期2019-05 启动
  80. Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer状态不明NCT03926091研究中心III期2019-04 启动
  81. Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer状态不明NCT04165993研究中心II期2019-12 启动
  82. Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC进行中,不再招募NCT03562637研究中心III期2018-12 启动
  83. A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer已完成NCT03371017研究中心III期2018-01 启动
  84. The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer状态不明NCT04185649研究中心III期2018-07 启动
  85. A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases状态不明NCT03500380研究中心II/III期2018-04 启动
  86. Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)进行中,不再招募NCT03725059研究中心III期2018-12 启动
  87. A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer已终止NCT03498716研究中心III期2018-08 启动
  88. Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China已完成NCT03575065研究中心II期2018-06 启动
  89. DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]已完成NCT03529110研究中心III期2018-08 启动
  90. Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment已完成NCT04085276研究中心III期2018-12 启动
  91. A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.状态不明NCT04385563研究中心III期2018-11 启动
  92. Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]已完成NCT03734029研究中心III期2018-12 启动
  93. Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer状态不明NCT03692689研究中心II期2018-07 启动
  94. A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)已完成NCT03125902研究中心III期2017-08 启动
  95. Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy进行中,不再招募NCT03315364研究中心II/III期2017-12 启动
  96. Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer进行中,不再招募NCT03155997研究中心III期2017-07 启动
  97. Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer已完成NCT03084939研究中心III期2017-04 启动
  98. Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer状态不明NCT03351062研究中心III期2017-11 启动
  99. Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer已完成NCT03084237研究中心III期2016-11 启动
  100. A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast状态不明NCT03047889研究中心2016-04 启动
  101. A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer已完成NCT02896855研究中心III期2016-09 启动
  102. Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer进行中,不再招募NCT02455141研究中心III期2016-03 启动
  103. Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel已完成NCT02586025研究中心III期2016-03 启动
  104. Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women状态不明NCT02914158研究中心III期2016-03 启动
  105. Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)已完成NCT02568267研究中心II期2015-11 启动
  106. Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer已完成NCT02499146研究中心I期2015-09 启动
  107. A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]已完成NCT02297438研究中心III期2015-03 启动
  108. Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer已完成NCT02482753研究中心III期2015-07 启动
  109. Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer已完成NCT02253459研究中心III期2014-08 启动
  110. Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients状态不明NCT01939054研究中心II期2013-09 启动
  111. A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)已完成NCT01772472研究中心III期2013-04 启动
  112. A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment已完成NCT01702571研究中心III期2012-11 启动
  113. Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer状态不明NCT01492556研究中心II期2011-12 启动
  114. A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer已完成NCT01358877研究中心III期2011-11 启动
  115. Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China已完成NCT01176916研究中心IV期2011-02 启动
  116. Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer已完成NCT02613026研究中心III期2009-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胶质瘤

Glioma

2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.2%。

牵头论文
14
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 4420232024: 2220242025: 442025

哈尔滨有 4 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胶质瘤开放试验。

这些数字背后的记录
论文中的科室神经外科放疗科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文14
  1. Targeting BACH1 by HPPE inhibits the Wnt/β-catenin pathway and malignant phenotype in glioblastoma cells.2025Apoptosis : an international journal on programmed cell death
  2. Role of SIX5-mediated EXO1 overexpression in driving glioblastoma progression: Insights into tumor cell migration and angiogenesis.2025Brain research
  3. Multi-omics-guided characterization of neoantigens improves patient stratification and potentiates combinatorial immunotherapy in glioma.2025Cell reports
  4. Correlation of miR-3188 with patient prognosis and mechanistic inhibition of glioma proliferation, invasion, and migration by targeting MAPK1.2025Folia neuropathologica
  5. Intraoperative radiotherapy in recurrent IDH-wildtype glioblastoma with gross total resection: A single-center retrospective study.2024Clinical neurology and neurosurgery
  6. The Relationship Between the Molecular Phenotypes of Brain Gliomas and the Imaging Features and Sensitivity of Radiotherapy and Chemotherapy.2024Clinical oncology (Royal College of Radiologists (Great Britain))
  7. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.2023Functional & integrative genomics
  8. Reply to: Comments on "New insights into glioma frequency maps: From genetic and transcriptomic correlate to survival prediction".2023International journal of cancer
  9. New insights into glioma frequency maps: From genetic and transcriptomic correlate to survival prediction.2023International journal of cancer免费全文
  10. RPL34-Divergent Transcript, a Novel Long NonCoding Ribonucleic Acid, Promotes Migration by Activating Epithelial-Mesenchymal Transition in Glioma.2023World neurosurgery
  11. Circular RNA circBFAR promotes glioblastoma progression by regulating a miR-548b/FoxM1 axis.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  12. GBAS Regulates the Proliferation and Metastasis of Ovarian Cancer Cells by Combining with eEF1A1.2022The oncologist免费全文
  13. Circular RNA circHECTD1 facilitates glioma progression by regulating the miR-296-3p/SLC10A7 axis.2021Journal of cellular physiology
  14. circFLNA promotes glioblastoma proliferation and invasion by negatively regulating miR‑199‑3p expression.2021Molecular medicine reports免费全文

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.09%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

哈尔滨有 6 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

哈尔滨有 5 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    发布
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.4%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 0020232024: 1120242025: 112025

哈尔滨有 3 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    发布
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 正在招募
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-06
    发布
    登记号
    NCT06574568

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、哈尔滨、太原、广州、杭州、济南、郑州

  3. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    发布
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层CAR-T 与细胞治疗联合用药

这些论文过半是实验室或动物研究。

牵头的论文6
  1. HNRNPA2B1 Promotes the Progression of Multiple Myeloma via Endoplasmic Reticulum Stress and Autophagy Mediated by CK2 Kinase.2025Journal of proteome research
  2. Prognostic marker CD27 and its micro-environmental in multiple myeloma.2024BMC cancer免费全文
  3. Non-invasive discrimination of multiple myeloma using label-free serum surface-enhanced Raman scattering spectroscopy in combination with multivariate analysis.2022Analytica chimica acta
  4. IP-10 enhances the amplification capacity and antitumor activity of CAR-T cells in vitro and could influence positive outcomes in MM patients treated with CAR-T cell therapy.2022International immunopharmacology
  5. HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma.2022Journal of translational medicine免费全文
  6. Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma.2021Journal of proteome research
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  2. A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT06574568研究中心I期2024-06 启动
  3. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  4. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  5. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.已完成NCT05228470研究中心II期2021-12 启动
  6. A Study of Ninlaro in Real World Clinical Practice in China已完成NCT04328662研究中心2020-05 启动
  7. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  8. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy已完成NCT02609828研究中心III期2015-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

淋巴瘤

Lymphoma

2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 26 篇,占 0.7%。

牵头论文
26
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
12
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 2220222023: 5520232024: 8820242025: 772025

哈尔滨有 3 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下

这家医院参与的开放试验 12

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
    分期
    III期
    开始
    2026-03
    发布
    登记号
    NCT07409428

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 42 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、合肥、哈尔滨、天津、太原、广州、徐州、成都、杭州、武汉、沈阳、泉州、济南、福州、蚌埠、西安、贵阳、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
    分期
    III期
    开始
    2025-03
    发布
    登记号
    NCT06742996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、临沂、北京、南京、南昌、哈尔滨、广州、徐州、成都、杭州、武汉、沈阳、温州、郑州、重庆、青岛

  3. 正在招募
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
    分期
    I/II期
    开始
    2025-04
    发布
    登记号
    NCT06829771

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、兰州、北京、哈尔滨、天津、太原、广州、徐州、武汉、泉州、泸州、烟台、福州、蚌埠、西安、郑州、长春

  4. 正在招募
    Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
    分期
    II期
    开始
    2025-03
    发布
    登记号
    NCT06854445

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 21 家列出的医院为研究中心兰州、南京、南宁、南昌、厦门、哈尔滨、大连、太原、杭州、武汉、泸州、济南、石家庄、芜湖、苏州、西安、郑州、长沙

  5. 正在招募
    A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
    分期
    III期
    开始
    2025-06
    发布
    登记号
    NCT06943872

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、呼和浩特、哈尔滨、天津、广州、成都、扬州、无锡、杭州、武汉、沈阳、济南、石家庄、福州、重庆、长沙、青岛

  6. 正在招募
    An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
    分期
    未注明
    开始
    2025-09
    发布
    登记号
    NCT07200375

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、北京、南昌、哈尔滨、天津、宁波、广州、成都、武汉、济南、温州、烟台、西安、郑州、长春

  7. 正在招募
    A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06566586

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、乌鲁木齐、兰州、南宁、南昌、呼和浩特、哈尔滨、天津、太原、广州、武汉、泸州、西安、郑州、长沙

  8. 正在招募
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT07234162

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、兰州、北京、南京、南宁、厦门、合肥、哈尔滨、天津、太原、广州、成都、杭州、武汉、沈阳、济南、温州、福州、西安、郑州、重庆、长春、长沙

  9. 正在招募
    First in Human, Dose Escalation Study of AN4005
    分期
    I期
    开始
    2021-09
    发布
    登记号
    NCT04999384

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、哈尔滨、武汉

  10. 即将招募
    Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
    分期
    II/III期
    开始
    2026-09
    发布
    登记号
    NCT07712588

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、哈尔滨、重庆、长沙

  11. 即将招募
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    分期
    III期
    开始
    2026-10
    发布
    登记号
    NCT07896590

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 40 家列出的医院为研究中心上海、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、洛阳、济南、海口、石家庄、福州、西安、郑州、重庆、长沙

  12. 即将招募
    Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
    分期
    II期
    开始
    2025-10
    发布
    登记号
    NCT07206264

    年龄 60 岁 至 未注明(登记的条件)

    牵头:天津医科大学肿瘤医院;另有 3 家列出的医院为研究中心哈尔滨、天津、济南、福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科放疗科影像/核医学科
牵头的论文26
  1. Feasibility analysis of metabolic parameters based on baseline 18F-FDG PET/CT to predict heterogeneity and recurrence of diffuse large B-cell lymphoma.2025Annals of hematology免费全文
  2. Genomic mutation profile and metabolic alterations in diffuse large B-cell lymphoma with abdominal bulky mass.2025Annals of hematology免费全文
  3. The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients.2025Annals of hematology
  4. BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies.2025Blood reviews
  5. Upregulated miR-29a-3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1.2025Hematological oncology
  6. Effect of metabolic syndrome on prognosis in patients with peripheral T-cell lymphoma.2025Hematology (Amsterdam, Netherlands)
  7. Factors affecting refractoriness or recurrence in diffuse large B-cell lymphoma: development and validation of a novel predictive nomogram.2025Hematology (Amsterdam, Netherlands)
  8. Fat mass and obesity-associated protein (FTO)-induced upregulation of flotillin-2 (FLOT2) contributes to cancer aggressiveness in diffuse large B-cell lymphoma (DLBCL) via activating the PI3K/Akt/mTOR signal pathway.2024Archives of biochemistry and biophysics
  9. Pyroptotic macrophages promote proliferation and chemotherapy resistance of peripheral T-cell lymphoma via TLR4 signaling pathway.2024Cancer science免费全文
  10. A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico免费全文
  11. The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico免费全文
  12. High PPP4C expression predicts poor prognosis in diffuse large B-cell lymphoma.2024Clinical and experimental medicine免费全文
  13. Rare Metastatic Embryonal Carcinoma Resembling Lymphoma: A Case Report.2024Current medical imaging
  14. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma.2024Discovery medicine
  15. Joint Analysis of CCAAT/Enhancer-Binding Protein Beta and Interleukin 1 Beta in the Treatment and Prognosis of Diffuse Large B-Cell Lymphoma.2024Frontiers in bioscience (Landmark edition)
  16. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.2023Autoimmunity
  17. Development and validation of a [18F]FDG PET/CT-based radiomics nomogram to predict the prognostic risk of pretreatment diffuse large B cell lymphoma patients.2023European radiology免费全文
  18. Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma.2023Experimental biology and medicine (Maywood, N.J.)免费全文
  19. A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy.2023Journal of cancer research and clinical oncology免费全文
  20. MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway.2023PeerJ免费全文
  21. A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma.2022Leukemia & lymphoma
  22. Diagnosis and staging of diffuse large B-cell lymphoma using label-free surface-enhanced Raman spectroscopy.2022Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  23. High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study.2021BMC pharmacology & toxicology免费全文
  24. Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas.2021Brain tumor pathology
  25. Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy.2021Current oncology (Toronto, Ont.)免费全文
  26. Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma.2021Journal for immunotherapy of cancer免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)44
  1. A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL正在招募NCT07409428研究中心III期2026-03 启动
  2. Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma即将招募NCT07896590研究中心III期2026-10 启动
  3. Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)即将招募NCT07712588研究中心II/III期2026-09 启动
  4. A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)正在招募NCT06943872研究中心III期2025-06 启动
  5. Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment即将招募NCT07206264研究中心II期2025-10 启动
  6. An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma正在招募NCT07200375研究中心2025-09 启动
  7. Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma正在招募NCT06829771研究中心I/II期2025-04 启动
  8. A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)正在招募NCT06742996研究中心III期2025-03 启动
  9. Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma正在招募NCT06854445研究中心II期2025-03 启动
  10. A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma正在招募NCT06566586研究中心II期2024-11 启动
  11. A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)正在招募NCT07234162研究中心III期2024-05 启动
  12. First in Human, Dose Escalation Study of AN4005正在招募NCT04999384研究中心I期2021-09 启动
  13. Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers进行中,不再招募NCT07162181研究中心II期2025-08 启动
  14. A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors进行中,不再招募NCT06970743研究中心III期2025-05 启动
  15. Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL已完成NCT06601504研究中心II期2024-11 启动
  16. A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma进行中,不再招募NCT06508658研究中心III期2024-08 启动
  17. An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma进行中,不再招募NCT06047080研究中心III期2023-09 启动
  18. A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)进行中,不再招募NCT05578976研究中心III期2023-02 启动
  19. HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma已完成NCT05190068研究中心I期2022-01 启动
  20. A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma进行中,不再招募NCT05100862研究中心III期2022-03 启动
  21. A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma已完成NCT04657302研究中心I期2021-01 启动
  22. A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma进行中,不再招募NCT04408638研究中心III期2021-02 启动
  23. A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)已完成NCT04849416研究中心II期2021-05 启动
  24. A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)已完成NCT04660799研究中心II期2021-02 启动
  25. Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib已完成NCT05068440研究中心II期2021-08 启动
  26. A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma进行中,不再招募NCT04712097研究中心III期2021-10 启动
  27. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma已完成NCT03992339研究中心II期2020-04 启动
  28. A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).已终止NCT04236141研究中心III期2020-07 启动
  29. Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma已终止NCT04486391研究中心III期2020-12 启动
  30. Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma已终止NCT04002622研究中心II期2019-08 启动
  31. A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation进行中,不再招募NCT04002297研究中心III期2019-08 启动
  32. BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)已完成NCT03520920研究中心II期2018-01 启动
  33. Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™已完成NCT03263026研究中心III期2018-03 启动
  34. A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas已完成NCT03809767研究中心I期2018-10 启动
  35. Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms已完成NCT03493451研究中心II期2018-04 启动
  36. A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma已完成NCT03332017研究中心II期2017-11 启动
  37. Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma状态不明NCT03374007研究中心I期2017-10 启动
  38. Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma已完成NCT03145064研究中心II期2017-06 启动
  39. A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)已完成NCT02838420研究中心III期2016-08 启动
  40. A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients已完成NCT02945215研究中心I期2016-12 启动
  41. Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies已完成NCT02795182研究中心I期2016-06 启动
  42. Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)已完成NCT02568267研究中心II期2015-11 启动
  43. A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)已终止NCT01287741研究中心III期2011-07 启动
  44. A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)已完成NCT01332968研究中心III期2011-07 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年没有牵头范可尼贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

哈尔滨有 1 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

哈尔滨有 4 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

哈尔滨医科大学附属肿瘤医院

Harbin Medical University Cancer Hospital

哈尔滨

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Harbin medical university cancer hospital; Third Affiliated Hospital of Harbin Medical University; 哈尔滨医科大学第三临床医学院

提出更正下载数据